07/052021

Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question

To evaluate the immunogenicity of the Ad26.COV2.S vaccine Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in Immunogenicity of the Ad26.COV2.S Vaccine for Stephenson KE et https://pubmed.ncbi.nl (by Janssen 20‐Apr‐2021 JAMA RCT USA NCT04436276 humans, including the kinetics, COVID‐19 al m.nih.gov/33704352/ Pharmaceutical magnitude, and phenotype of SARS‐ Companies) CoV‐2 spike‐specific humoral and cellular immune responses

Combination of To compare the rate and time of Effect of a combination of nitazoxanide, https://www.ncbi.nlm.ni nitazoxanide, viral clearance in subjects receiving J of Medical ribavirin, and ivermectin plus zinc supplement h.gov/pmc/articles/PMC ribavirin, and the combination of nitazoxanide, 11‐Mar‐2021 CT Egypt Elalfy H et al NCT04392427 Virology (MANS.NRIZ study) on the clearance of mild 8014583/pdf/JMV‐9999‐ ivermectin plus Zinc ribavirin, and ivermectin plus zinc COVID‐19 0.pdf vs supportive versus those receiving supportive treatment treatment.

XAV‐19 0.5 mg/kg at Pharmacokinetics and safety of XAV‐19, a day 1 and day 5 To assess the pharmacokinetics and https://www.medrxiv.or swine glyco‐humanized polyclonal anti‐ SARS‐ (group 1), 2 mg/kg at safety of XAV‐19, a swine glyco‐ g/content/10.1101/2021 20‐Apr‐2021 MedRxiv CoV‐2 antibody, for COVID‐19‐related RCT France Gaborit B et al NCT04453384 day 1 and day 5 humanized polyclonal antibody .04.15.21255549v1.full.p (group 2), 2 mg/kg at against SARS‐CoV‐2, in COVID‐19‐ moderate pneumonia: a randomized, double‐ df blind, placebo‐controlled, phase IIa study day 1 (group 3) or related moderate pneumonia placebo

https://www.nejm.org/ To assest the Safety and Efficacy of Safety and Efficacy of Single‐Dose Ad26.COV2.S Vaccine RCT III 21‐Apr‐21 NEJM International Sadoff J et al. doi/10.1056/NEJMoa210 NCT04505722 Ad26.COV2.S vaccine Single‐Dose Ad26.COV2.S Vaccine Vaccine against Covid‐19 phase 1544 against Covid‐19

https://ashpublications. org/blood/article/doi/10 Efficacy of the BNT162b2 mRNA COVID‐19 Vaccine .1182/blood.202101156 BNT162b2 mRNA To determine the efficacy of COVID‐ 16‐Apr‐21 Blood Vaccine trial Israel Herishanu Y, et al. NCT04746092 in Patients with Chronic Lymphocytic Leukemia 8/475742/Efficacy‐of‐ COVID19 vaccine 19 vaccine in patients with CLL. the‐BNT162b2‐mRNA‐ COVID‐19‐Vaccine‐in

https://journals.lww.co Immunogenicity and safety of a SARS‐CoV‐2 ChiCTR2000038 To assess the immunogenicity and Chinese m/cmj/Abstract/9000/I inactivated vaccine in healthy adults randomized, vaccine RCT I/II 804, KCONVAC ‐ SARS‐CoV‐ safety of an inactivated SARS‐CoV‐2 28‐Apr‐21 Medical China Pan HX, et al. mmunogenicity_and_saf double‐blind, and placebo‐controlled phase 1 and phase ChiCTR2000039 2 inactivated vaccine vaccine, KCONVAC, in healthy Journal ety_of_a_SARS_CoV_2.9 phase 2 clinical trials 462 adults. 8627.aspx To determine whether Effect of Early Treatment With Hydroxychloroquine https://jamanetwork.co hydroxychloroquine or lopinavir‐ JAMA Netw or Lopinavir and Ritonavir on Risk of Hospitalization m/journals/jamanetwor hydroxychloroquine ritonavir reduces hospitalization 22‐Apr‐21 RCT International Reis G et al. NCT04403100 Open. Among Patients With COVID‐19 kopen/fullarticle/277904 or lopinavir‐ritonavir among high‐risk patients with early The TOGETHER Randomized Clinical Trial 4 symptomatic COVID‐19 in an outpatient setting.

https://search.bvsalud.o to evaluate rg/global‐literature‐on‐ whether pyridostigmine could Pyridostigmine in adults with severe SARS‐CoV‐2 Fragoso‐Saavedra S, decrease invasive mechanical 5‐May‐21 MedRxiv RCT Mexico novel‐coronavirus‐2019‐ NCT04343963 pyridostigmine infection: the PISCO trial et al. ventilation (IMV) ncov/resource/en/ppme and death in patients with severe drxiv‐21255834 COVID-19

Impact and effectiveness of mRNA BNT162b2 https://www.thelancet.c vaccine against SARS‐CoV‐2 infections and COVID‐19 om/journals/lancet/artic Real‐world effectiveness of two 5‐May‐21 The Lancet cases, hospitalisations, and deaths following a Observational study Israel Haas et al. le/PIIS0140‐ NA BNT162b2 doses of BNT162b2 against SARS‐ nationwide vaccination campaign in Israel: an 6736(21)00947‐ CoV‐2 observational study using national surveillance data 8/fulltext

Horby et al. https://www.thelancet.c What is the effect of tocilizumab in Tocilizumab in patients admitted to hospital with (RECOVERY om/action/showPdf?pii= adult patients admitted to hospital 1‐May‐21 The Lancet COVID‐19 (RECOVERY): a randomised, controlled, RCT UK NCT04381936 Tocilizumab Collaborative S0140‐ with open‐label, platform trial Group) 6736%2821%2900676‐0 COVID‐19

Safety and immunogenicity of one versus two doses of https://www.thelancet.c To assess the safety and The Lancet the COVID‐19 vaccine BNT162b2 for patients with om/action/showPdf?pii= immunogenicity of the BNT162b2 27‐Apr‐21 Observational study UK Manin et al. NA BN162b2 vaccine Oncology cancer: interim analysis of a prospective observational S1470‐ (Pfizer–BioNTech) vaccine in study 2045%2821%2900213‐8 patients with cancer

To evaluate the efficacy of the Lancet Ramakrishnan S., inhaled glucocorticoid widely used inhaled glucocorticoid 9‐Apr‐21 tment of early COVID 19 (STOIC): a phase 2, open‐lab RCT 2 phase UK ournals/lanres/article/PIIS NCT04416399 Respir Med. et al. budesonide budesonide in individuals with early COVID‐19 in the community.

https://www.thelancet.c Efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine post‐hoc analysis of the efficacy of om/journals/lancet/artic against SARS‐CoV‐2 variant of concern 202012/01 Emary K.R.W., et ChAdOx1 nCoV 19 the adenoviral vector vaccine, 30‐Mar‐21 Lancet vaccine UK le/PIIS0140‐ NCT04400838 (B.1.1.7): an exploratory analysis of a randomised al (AZD1222) vaccine ChAdOx1 nCoV‐19 (AZD1222), 6736(21)00628‐ controlled trial against the variant B.1.1.7. 0/fulltext

Methylprednisolone or dexamethasone, which one https://bmcinfectdis.bio To assess the effectiveness of BMC is superior corticosteroid in the treatment of medcentral.com/articles IRCT202002040 Methylprednisolone methylprednisolone treatment 10‐Apr‐21 Infectious RCT Iran Ranjbar B hospitalized COVID‐19 patients: a triple‐blinded /10.1186/s12879‐021‐ 46369N1 or dexamethason versus dexamethasone for Diseases randomized controlled trial 06045‐3 hospitalized COVID‐19 patients. Two phase 1 and Immunogenicity and Safety of a SARS‐CoV‐2 phase 2 https://www.medrxiv.or To report the immunogenicity and NCT04758273 Inactivated Vaccine (KCONVAC) in Healthy Adults: randomized, double‐ g/content/10.1101/2021 safety of a SARS‐CoV‐2 inactivated 8‐Apr‐2021 MedRxiv China Pan H et al AND KCONVAC Two Randomized, Double‐blind, and Placebo‐ blind, and placebo‐ .04.07.21253850v1.full.p vaccine, KCONVAC, in healthy NCT04756323 controlled Phase 1/2 Clinical Trials controlled trials of df adults. KCONVAC

INTERIM REPORT: SAFETY AND IMMUNOGENICITY https://www.medrxiv.or Interim analysis of a To evaluate safety parameters and OF AN INACTIVATED VACCINE AGAINST SARS‐COV‐2 g/content/10.1101/2021 1‐Apr‐2021 MedRxiv multicenter phase 3 Chile Bueno SM et al NCT04651790 CoronaVac immunogenicity against SARS‐CoV‐2 IN HEALTHY CHILEAN ADULTS IN A PHASE 3 .03.31.21254494v1.full.p CT after immunization with CoronaVac CLINICAL TRIAL df

To assess the effect of oral Ivermectin treatment, which has been associated with iota‐ carrageenan in repeated doses A RANDOMIZED TRIAL ‐ INTENSIVE TREATMENT https://www.medrxiv.or through the nasal and BASED IN IVERMECTIN AND IOTA‐CARRAGEENAN g/content/10.1101/2021 Ivermectin / oral topical route, on the 30‐Mar‐2021 MedRxiv RCT Argentina Chahla RE et al NCT04701710 AS PRE‐EXPOSURE PROPHYLAXIS FOR COVID‐ 19 IN .03.26.21254398v1.full.p IotaCarrageenan appearance and eventual HEALTHCARE AGENTS df progression of COVID‐19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS‐ COV‐2

To assess the use of a nasal spray Efficacy of a nasal spray containing Iota‐ https://www.medrxiv.or Nasal spray CARR‐COV2 Trial containing I‐C in the prophylaxis of Carrageenan in the prophylaxis of COVID‐ 19 in RCT g/content/10.1101/2021 containing Iota‐ 15‐Apr‐2021 MedRxiv Argentina Group NCT04521322 COVID‐19 in hospital personnel hospital personnel dedicated to patients care (CARR‐COV‐02) .04.13.21255409v1.full.p Carrageenan (I‐C) or dedicated to care of COVID‐19 collaborators df placebo for 21 days. with COVID‐19 disease patients

to report the occurrence of https://www.medrxiv.or Performance of vaccination with CoronaVac in symptomatic COVID‐19 in a cohort g/content/10.1101/2021 15‐Apr‐2021 MedRxiv a cohort of healthcare workers (HCW) ‐ preliminary report Brazil De Faria E et al NA CoronaVac of healthcare workers (HCW) .04.12.21255308v1.full.p vaccinated with CoronaVac and to preliminary report df estimate its effectiveness.

RBD‐specific polyclonal F(ab )2 fragments of equine phase 2/3, double‐ To analyze the safety and efficacy of antibodies in patients with moderate to severe https://www.ncbi.nlm.ni EClinicalMedi blind, placebo‐con‐ Equine poly‐ clonal specific anti SARS‐COV‐2 EpAbs in 8‐Apr‐2021 COVID‐19 disease: A randomized, multicenter, Argentina Lopardo et al h.gov/pmc/articles/PMC NCT04494984 cine trolled, multicenter antibodies (EpAbs) hospitalized patients with mod‐ double‐blind, placebo‐controlled, adaptive phase 8037439/pdf/main.pdf clinical erate and severe COVID‐19 disease 2/3 clinical trial

Diphenhydramine Compound (Diphenhydramine + Quaternary ammonium compounds Int J of Effect of Ammonium Chloride in addition to double‐blind, single‐ https://pubmed.ncbi.nl Ammonium Chloride) have been demonstrated to have 12‐Apr‐2021 Infectious standard of care in outpatients and hospitalized Iran Siami Z et al NA center study m.nih.gov/33878462/ plus standard of care antiviral effects and may be of use Diseases COVID‐19 patients: a randomized clinical trial or Diphenhydramine against SARS‐CoV‐2 infections. alone and standard of care groups

To determine any possible effects three‐armed, and safety concerns of the two https://www.nature.co Scientific Role of interferon therapy in severe COVID‐19: the individually‐randomi most promising exogenously 13‐Apr‐2021 Iran Darazam IA et al m/articles/s41598‐021‐ NCT04343768 IFNβ1a and IFNβ1b reports COVIFERON randomized controlled trial zed, open‐label, administrable IFNs on the course 86859‐y controlled trial and outcomes of patients hospitalized with severe COVID‐19.

180 mcg Peginterferon Lambda‐1a for treatment of randomized, single‐ To evaluate the efficacy of Lambda https://pubmed.ncbi.nl subcutaneous dose of 30‐Mar‐2021 Nature Comm outpatients with uncomplicated COVID‐19: a blind, placebo‐ USA Jagannathan P et al NCT04331899 in reducing the duration of viral m.nih.gov/33785743/ Peginterferon Lambda‐ randomized placebo‐controlled trial controlled trial shedding in outpatients. 1a (Lambda) ZF2001 Vaccine ‐ protein subunit Safety and immunogenicity of a recombinant vaccine against COVID‐ To assess the safety and The Lancet tandem‐repeat dimeric RBD‐based protein subunit 19 using a dimeric immunogenicity of this vaccine, 24‐Mar‐21 Infectious vaccine (ZF2001) against COVID‐19 in adults: two CT ‐ vaccine ‐ phase I/ China ShilongYang, et al. m/science/articleS147334045194 and NCT04 form of the receptor‐ ZF2001, and determine the Diseases randomised, double‐blind, placebo‐controlled, binding domain (RBD) appropriate dose and schedule for phase 1 and 2 trials of the SARS‐CoV‐2 an efficacy study. spike protein as the antigen

Clinical effectiveness of drugs in hospitalized To assess the clinical effectiveness 25‐Mar‐21 dvances in Resp patients with COVID‐19: a systematic review and meta‐analysis Mexico Zuñiga RAA, et al. gepub.com/doi/10.1177/1 NA ne, lopinavir, ritonavir, of drugs used in hospitalized meta‐analysis patients with COVID‐19 infection.

To assess whether helmet Effect of Helmet Noninvasive Ventilation vs High‐ noninvasive ventilation can increase Flow Nasal Oxygen on Days Free of Respiratory the days free of respiratory support 25‐Mar‐21 JAMA Support in Patients With COVID‐19 and Moderate to RCT InternationalDomenico Luca Griecwoork.com/journals/jama/fu NCT04502576 oxygen in patients with COVID‐19 Severe Hypoxemic Respiratory Failure The HENIVOT compared with high‐flow nasal Randomized Clinical Trial oxygen alone.

Effect of Intermediate‐Dose vs Standard‐Dose To evaluate the effects of Prophylactic Anticoagulation on Thrombotic Events, intermediate‐dose vs standard‐dose Extracorporeal Membrane Oxygenation Treatment, 18‐Mar‐21 JAMA RCT Iran SPIRATION Investigatwoork.com/journals/jama/fu NCT04486508 dard prophylactic anticoprophylactic anticoagulation among or Mortality Among Patients With COVID‐19 patients with COVID‐19 admitted to Admitted to the Intensive Care Unit The the intensive care unit (ICU) INSPIRATION Randomized Clinical Trial

Safety and immunogenicity of an inactivated SARS‐ https://www.thelancet.c CoV‐2 vaccine, BBV152: interim results from a om/journals/laninf/articl To evaluate the safety and Lancet Infect BBV152 (Bharat 8‐Mar‐2021 double blind, randomised, mulcentre, phase 2 Vaccine trial Phase II India Ella R., et al. e/PIIS1473‐ NCT04471519 immunogenicity of an inactivated Dis Biotech) vaccine trial, and 3‐month follow‐up of a double‐blind, 3099(21)00070‐ SARS‐CoV‐2 vaccine, BBV152. randomised phase 1 trial 0/fulltext Effect of Ivermectin on Time to Resolution of https://jamanetwork.co To determine whether ivermectin is Colombia/US Lopez‐Medina E., 4‐Mar‐2021 JAMA Symptoms Among Adults With Mild COVID‐19A RCT Phase III m/journals/jama/fullarti NCT04405843 Ivermectin an efficacious treatment for mild A et al. Randomized Clinical Trial cle/2777389 COVID‐19.

To assess safety and efficacy of sarilumab, an interleukin‐6 receptor https://www.thelancet.c inhibitor, in patients with severe Sarilumab in patients admitted to hospital with om/journals/lanres/artic (requiring supplemental oxygen by Lancet Respir 4‐Mar‐2021 severe or crical COVID 19: a randomised, RCT Phase III International Lescure FX., et al. le/PIIS2213‐ NCT04327388 Sarilumab nasal cannula or face mask) or Med double blind, placebo‐controlled, phase 3 trial 2600(21)00099‐ critical (requiring greater 0/fulltext supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID‐19.

Azithromycin for community treatment of https://www.thelancet.c To assess the effectiveness of suspected COVID‐19 in people at increased risk of PRINCIPLE Trial om/journals/lancet/artic azithromycin to treat suspected ISRCTN8653458 4‐Mar‐2021 Lancet an adverse clinical course in the UK (PRINCIPLE): a RCT Phase III UK Collaborative le/PIIS0140‐ Azithromycin COVID‐19 among people in the 0 randomised, controlled, open‐label, adaptive Group 6736(21)00461‐ community who had an increased platform trial X/fulltext risk of complications.

Molnupiravir, EIDD‐ Single and multiple doses of 2801/MK‐4482, molnupiravir were evaluated in this prodrug of the active first‐in‐human, phase 1, Antimicrob Human Safety, Tolerability, and Pharmacokinetics of https://aac.asm.org/con antiviral randomized, double‐blind, 1‐Mar‐2021 Agents Molnupiravir, a Novel Broad‐Spectrum Oral RCT Phase I USA Painter W. P., et al. tent/early/2021/02/24/ NCT04392219 ribonucleoside analog placebocontrolled study in healthy Chemother Anviral Agent with Acvity Against SARS‐CoV 2 AAC.02428‐20 14ß‐d‐N4‐ volunteers, which included hydroxycytidine (NHC; evaluation of the effect of food on EIDD‐1931) pharmacokinetics.

To evaluate the immunogenicity of the Ad26.COV2.S vaccine Immunogenicity of the (Janssen/Johnson & Johnson) in Immunogenicity of the Ad26.COV2.S Vaccine for Kathryn E. Ad26.COV2.S Vaccine for Ad26.COV2.S Vaccine 11‐Mar‐2021 JAMA Vaccine trial Phase I USA NCT04436276 humans, including the kinetics, COVID‐19 Stephenson COVID‐19 | Vaccination (Janssen) magnitude, and phenotype of SARS‐ | JAMA | JAMA Network CoV‐2 spike‐specific humoral and cellular immune responses.

To assess the efficacy and safety of Signal Effect of human umbilical cord‐derived Human umbilical cord‐ human umbilical cord‐mesenchymal Transduct mesenchymal stem cells on lung damage in severe https://pubmed.ncbi.nl 10‐Feb‐2021 Vaccine trial Phase I/II China Shi et el. NCT04288102 derived mesenchymal stem cells (UC‐MSCs) to treat severe Target Ther COVID‐19 patients: a randomized, double‐blind, m.nih.gov/33568628/ stem cells COVID‐19 patients with lung placebo‐controlled phase 2 trial damage, based on our phase 1 data.

A preliminary report of a randomized controlled To evaluate the safety and A preliminary report of a randomized controlled phase 2 trial of the immunogenicity of vaccine 9‐Feb‐2021 Vaccine phase 2 trial of the safety and immunogenicity of RCT phase II US LaurenceChu safety and NCT04405076 mRNA‐1273 vaccine candidate mRNA‐1273, encoding mRNA‐1273 SARS‐CoV‐2 vaccine immunogenicity of the prefusion‐stabilized spike mRNA‐1273 SARS‐CoV‐2 protein of SARS‐CoV‐2. vaccine ‐ ScienceDirect https://www.ncbi.nlm.ni Early versus deferred anti‐SARS‐CoV‐2 convalescent To evaluate the efficacy and safety of h.gov/pmc/articles/PMC 03‐Mar‐21 Plos Med plasma in patients admitted for COVID‐19: A RCT Chile Balcells MA et al NCT04375098 Convalescent Plasma early Convalescent Plasma therapy in 7929568/pdf/pmed.100 randomized phase II clinical trial COVID‐19 progression 3415.pdf

Oral dose of Thrombosis To evaluate the effect of sulodexide Sulodexide in the treatment of patients with early Gonzalez Ochoa AJ https://pubmed.ncbi.nl sulodexide (500 LRU 07‐Mar‐21 and RCT Mexico ISRCTN59048638 when used in the early clinical stages of COVID‐19: a randomized controlled trial et al m.nih.gov/33677827/ twice a day) or Haemostasis stages of COVID‐19 placebo for 21 days

To assess the safety and efficacy of https://www.nejm.org/ the ChAdOx1 nCoV‐19 vaccine Efficacy of the ChAdOx1 nCoV‐19 Covid‐19 doi/pdf/10.1056/NEJMo ChAdOx1 nCoV‐19 16‐Mar‐21 NEJM RCT South Africa Madhi SA et al NCT04444674 (AZD1222) in people not infected Vaccine against the B.1.351 Variant a2102214?articleTools=t vaccine (AZD1222) with the human immunodeficiency rue virus (HIV) in South Africa.

Evaluation of the effectiveness of the https://www.nejm.org/ BNT162b2 mRNA Covid‐19 Vaccine in a Nationwide BNT162b2 mRNA Covid‐ BNT162b2 mRNA vaccine based on 24‐Feb‐21 NEJM Vaccine Israel Dagan N., et al. doi/10.1056/NEJMoa210 NA Mass Vaccination Setting 19 Vaccine data from Israel’s largest health care 1765 organization.

Exploratory analyses of the impact on https://www.thelancet.c immunogenicity and efficacy of Single‐dose administration and the influence of the om/journals/lancet/artic extending the interval between priming timing of the booster dose on immunogenicity and ChAdOx1 nCoV‐19 19‐Feb‐21 Lancet Vaccine UK Voysey M., et al. le/PIIS0140‐ NA and booster doses. efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine: a vaccine ‐ Immunogenicity and protection pooled analysis of four randomised trials 6736(21)00432‐ 3/fulltext afforded by the first dose, before a booster dose has been offered.

https://www.thelancet.c om/journals/lancet/artic To examine early reductions in SARS‐ Early rate reductions of SARS‐CoV‐2 infection and COVID‐ 18‐Feb‐21 Lancet Vaccine Israel Amit S., et al. le/PIIS0140‐ NA BNT162b2 vaccine CoV‐2 infection and COVID19 rates in 19 in BNT162b2 vaccine recipients 6736(21)00448‐ vaccinated HCWs. 7/fulltext

Association of Convalescent Plasma Treatment With https://jamanetwork.co Is treatment with convalescent plasma 28‐Feb‐21 JAMA Clinical Outcomes in Patients With COVID‐19 A Metaanalysis International Janiaud et al. m/journals/jama/fullarti NA convalescent plasma associated with improved clinical Systematic Review and Meta‐analysis cle/2777060 outcomes?

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With To investigate the effect of a single Effect of a Single High Dose of Vitamin D3 on Hospital Moderate to Severe high dose of vitamin D3 on hospital 17‐Feb‐21 JAMA Length of Stay in Patients With Moderate to Severe RCT Brazil Murai et al. COVID‐19: A NCT04449718 Vitamin D3 length of stay in patients with COVID‐ COVID‐19. A Randomized Clinical Trial Randomized Clinical 19. Trial | Complementary and Alternative Medicine | JAMA | JAMA Network

To examine whether high‐dose zinc Effect of High‐Dose Zinc and Ascorbic Acid https://jamanetwork.co Zinc gluconate (50 mg), and/or high‐dose ascorbic acid reduce Supplementation vs Usual Care on Symptom Length and m/journals/jamanetwor ascorbic acid (8000 mg), the severity or duration of symptoms 12‐Feb‐21 JAMA Reduction Among Ambulatory Patients With SARS‐CoV‐2 RCT US Thomas et al. NCT04342728 kopen/fullarticle/277630 both agents, or compared with usual care among Infection standard of care. ambulatory patients with SARS‐CoV‐2 The COVID A to Z Randomized Clinical Trial 5 infection.

https://jamanetwork.co Whether nasopharyngeal application of Povidone Iodine Mouthwash, Gargle, and Nasal Spray to m/journals/jamaotolary Povidone iodine (PI) PI could reduce the viral load of 4‐Feb‐21 JAMA Reduce Nasopharyngeal Viral Load in Patients With RCT France Guenezan NCT04371965 ngology/fullarticle/2775 solutions. patients with nonsevere coronavirus COVID‐19. A Randomized Clinical Trial 984 disease 2019 (COVID‐19) symptoms.

Early Use of Corticosteroid May Prolong SARS‐CoV‐2 Efficacy and safety of corticosteroid Shedding in Non‐Intensive Care Unit Patients with COVID https://pubmed.ncbi.nlm.n 22‐Jan‐21 Respiration RCT China Tang et al. NCT04273321 methylprednisolone given to the hospitalized patients with 19 Pneumonia: A Multicenter, Single‐Blind, Randomized ih.gov/33486496/ COVID‐19 Control Trial https://erj.ersjournals.com European Early use of nitazoxanide in mild Covid‐19 disease: /content/erj/early/2021/0 Efficacy and safety of nitrazoxanide in Jan‐21 Respiratory RCT Brazil Rocco et al. NCT04552483 nitazoxanide randomised, placebo‐controlled trial 1/04/13993003.03725‐ COVID‐19 patients Journal 2020.full.pdf

https://stemcellsjournals.o Stem Cell Umbilical cord mesenchymal stem cells for COVID‐19 nlinelibrary.wiley.com/doi/ Jan‐21 Transplantatio acuterespiratory distress syndrome: A double‐blind, RCT USA Lanzoni et al. NCT04355728 mesenchymal stem cell Safety of MSC in COVID‐19 patients epdf/10.1002/sctm.20‐ n Medicine phase 1/2a,randomized controlled trial 0472

https://www.medrxiv.org/ Evaluation of a SARS‐CoV‐2 Vaccine NVX‐CoV2373 in Evaluation of a SARS‐CoV‐2 Vaccine 1‐Mar‐21 MedRxiv RCT USA Neil Formica et al content/10.1101/2021.02. NCT04368988 NVX‐CoV2373 vaccine Younger and Older Adults NVX‐CoV2373 26.21252482v1.full.pdf

https://www.ncbi.nlm.nih. Archives of Efficacy of favipiravir in COVID‐19 treatment: a gov/pmc/articles/PMC782 chloroquine and 25‐Jan‐21 RCT Egypt Dabbous HM et al NCT04351295 To evaluate the efficacy of favipiravir Virology multi‐center randomized study 9645/pdf/705_2021_Articl favipiravir e_4956.pdf

https://www.nejm.org/doi NCT04381936; To evaluate the effects of potential Horby P et al 25‐Feb‐21 NEJM Dexamethasone in Hospitalized Patients with Covid‐19 RCT UK /pdf/10.1056/NEJMoa202 ISRCTN number, dexamethasone treatments in patients hospitalized with (RECOVERY Group) 1436?articleTools=true 50189673 Covid‐19 at

https://www.nejm.org/doi To assess the efficacy and safety of Tocilizumab in Hospitalized Patients with Severe Covid‐ 25‐Feb‐21 NEJM RCT USA Rosas IO et al /pdf/10.1056/NEJMoa202 NCT04320615 tocilizumab tocilizumab in hospitalized patients 19 Pneumonia 8700?articleTools=true with severe Covid‐19 pneumonia

REMAP‐CAP https://www.nejm.org/doi To assess the efficacy of interleukin‐6 Interleukin‐6 Receptor Antagonists in Critically Ill Patients ClinicalTrials.gov tocilizumab and 25‐Feb‐21 NEJM RCT UK Gordon AC et al /pdf/10.1056/NEJMoa210 receptor antagonists in critically ill with Covid‐19 number, sarilumab 0433?articleTools=true patients with Covid‐19 NCT02735707

Effect of tocilizumab on clinical outcomes at 15 days in Does tocilizumab improves clinical https://www.bmj.com/c 20‐Jan‐21 BMJ patients with severe or critical coronavirus disease 2019: RCT Brazil Veiga, V.C. et al. NCT04403685 tocilizumab outcomes for patients with severe or ontent/372/bmj.n84 randomised controlled tria COVID‐19?. Interim Results of a Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Phase 1–2a Trial of NCT04436276. The safety and immunogenicity profiles 13‐Jan‐21 NEJM vaccine Phase I/IIa USA Sadoff J., et al. Ad26.COV2.S vaccine Covid‐19 Vaccine Ad26.COV2.S Covid‐19 opens in new tab. of Ad26.COV2 Vaccine | NEJM

To assess whether convalescent plasma https://www.medrxiv.or with high antibody levels rather than low antibody levels is Early Safety Indicators of COVID‐19 Convalescent Plasma expanded access g/content/10.1101/2020 13‐Jan‐21 NEJM USA Joyner et al. NCT04338360 Convalescent plasma associated with a lower risk of in 5,000 Patients program .05.12.20099879v1.full.p death. df Primary outcome: death within 30 days after plasma transfusion.

https://pmj.bmj.com/co Postgraduate Short term, high‐dose vitamin D supplementation for Do high doses of cholecalciferol lead to ntent/early/2020/11/12/ 11‐Nov‐20 Medical COVID‐19 disease: a randomised, placebo‐controlled, RCT India Rastogi et al. NCT04459247 Vitamin D SARS‐CoV‐2 negativity in greater postgradmedj‐2020‐ Journal study (SHADE study) proportions? 139065

https://www.thelancet.c Safety and immunogenicity of S‐Trimer (SCB‐2019), a om/journals/lancet/artic protein subunit vaccine candidate for COVID‐19 in Dose‐finding and adjuvant justification 29‐Jan‐21 The Lancet Phase I vaccine trial Multinational Richmond et al. le/PIIS0140‐ NCT04405908 S‐Trimer (SCB‐2019) healthy adults: a phase 1, randomised, double‐blind, of SCB‐2019 vaccine placebo‐controlled trial 6736(21)00241‐ 5/fulltext

https://www.thelancet.c Safety and efficacy of an rAd26 and rAd5 vector‐based om/journals/lancet/artic heterologous prime‐boost COVID‐19 vaccine: an interim Gam‐COVID‐Vac 02‐Feb‐21 The Lancet Phase III vaccine trial Russia Logunov et al. le/PIIS0140‐ NCT04530396 Efficacy and safety of Gam‐COVID‐Vac analysis of a randomised controlled phase 3 trial in (Sputnik V) Russia 6736(21)00234‐ 8/fulltext

Early High‐Titer Plasma Early High‐Titer Plasma Does convalescent plasma reduce the Therapy to Prevent 06‐Jan‐21 NEJM Therapy to Prevent Severe RCT Argentina Libster R, et al. NCT04479163 Convalescent plasma development of severe respiratory Severe Covid‐19 in Older Covid‐19 in Older Adults disease? Adults | NEJM

https://www.nejm.org/ Efficacy, Safety, and Immunogenicity of Efficacy and Safety of the mRNA‐1273 SARS‐CoV‐2 doi/full/10.1056/NEJMo mRNA‐1273 SARS‐CoV‐ 30‐Dec‐21 NEJM Vaccine ‐ phase III USA Baden LR, et al. NCT04470427 mRNA‐1273 Vaccine in Adults Aged 18 Vaccine a2035389?query=featur 2 Vaccine Years and Older to Prevent COVID‐19 ed_coronavirus https://www.medrxiv.or Enisamium is an inhibitor of the SARS‐CoV‐2 RNA g/content/10.1101/2021 Efficacy and safety of enisamium at 12‐Jan‐21 MedRxiv polymerase and shows improvement of recovery in RCT Multinational Holubovska et al. NCT04682873 enisamium .01.05.21249237v1.full‐ COVID‐19 patients COVID‐19 patients in an interim analysis of a clinical trial text

Safety and immunogenicity of SARS‐CoV‐2 recombinant https://www.medrxiv.or Safety and imunogenicity of CoV2 preS 20‐Jan‐21 MedRxiv protein vaccine formulations in healthy adults: a Vaccine trial phase I/II Multinational Goepfert et al. g/content/10.1101/2021 NCT04537208 CoV2 preS dTM vaccine dTM vaccine randomised, placebo‐controlled, dose‐ranging study .01.19.20248611v1

https://link.springer.co Annals of Pilot trial of high‐dose vitamin C in critically ill COVID‐19 09‐Jan‐21 RCT China Zhang et al. m/article/10.1186/s1361 NCT04264533 Vitamin C Effect of high doses of vitamin C Intensive Care patients 3‐020‐00792‐3

International Efficacy and safety of favipiravir, an oral RNA‐dependent https://www.sciencedir Efficacy and safety of favipiravir in Journal of RNA polymerase inhibitor, in mild‐to‐moderate COVID‐ ect.com/science/article/ CTRI/2020/05/02 01‐Feb‐21 RCT India Udwadia et al. favipiravir adults with mild‐to‐moderate COVID‐ Infectious 19: A randomized, comparative, open‐label, multicenter, pii/S120197122032453X 5114 19 Diseases phase 3 clinical trial ?via%3Dihub

https://www.thelancet.c ISRCTN89951424, Safety and efficacy of the ChAdOx1 nCoV‐19 vaccine om/journals/lancet/artic NCT04324606, (AZD1222) against SARS‐CoV‐2: an interim analysis of phase I/II/III vaccine ChAdOx1 nCoV‐19 To test the safety and efficacy of the 08‐Dec‐20 Lancet Multinational Voysey et al. le/PIIS0140‐ NCT04400838, four randomised controlled trials in Brazil, South Africa, trial vaccine ChAdOx1 nCoV‐19 vaccine and and the UK 6736(20)32661‐ 1/fulltext NCT04444674

Baricitinib plus Effect of Baricitinib plus Remdesivir for Hospitalized Adults with Remdesivir for Baricitinib plus baricitinib (≤14 days) plus remdesivir 11‐Dec‐20 NEJM RCT USA Kalil A.C., et al NCT04401579 Covid‐19 Hospitalized Adults with Remdesivir (≤10 days) vs. remdesivir alone Covid‐19 | NEJM in hospitalized adults with Covid‐19

https://www.nejm.org/ To test the safety and efficacy of Tocilizumab in Patients Hospitalized with Covid‐19 17‐Dec‐20 NEJM RCT USA Salama et al. doi/10.1056/NEJMoa203 NCT04372186 tocilizumab tocilizumab in hospitalized patients Pneumonia 0340 with Covid‐19 pneumonia

https://assets.researchs Exogenous Surfactant Versus Placebo in the Treatment quare.com/files/rs‐ IRCT2009120100 Is surfactant effective in COVID‐19 31‐Dec‐20 Preprint of Moderate and Severe ARDS in COVID19: The Pilot RCT Iran Ghahremani et al. 136365/v1/adcad24b‐ surfactant 2804N12 paients? Study of a Clinical Trial f7ed‐477b‐a235‐ 235f84f8ce1b.pdf

WHO mortality trial of four repurposed Repurposed Antiviral remdesivir, antiviral drugs — remdesivir, Repurposed Antiviral Drugs for Covid‐19 — Interim WHO WHO Soidarity Trial Drugs for Covid‐19 — hydroxychloroquine 02‐Dec‐20 NEJM RCT Multinational NCT04315948 hydroxychloroquine (HCQ), lopinavir, Solidarity Trial Results Consortium Interim WHO Solidarity (HCQ), lopinavir, and and interferon beta‐1a (IFN)— in interferon beta‐1a (IFN) Trial Results | NEJM patients hospitalized with Covid‐19.

Durability of Responses mRNA 1273 vaccine immunogenicity 3 Durability of Responses after SARS‐CoV‐2 mRNA‐ months after second 03‐Dec‐20 NEJM Phase I vaccine trial USA Widge A.T., et al. NCT04283461 mRNA 1273 vaccine after SARS‐CoV‐2 mRNA1273 Vaccination 1273 Vaccination | vaccination NEJM

Safety and immunogenicity of INO‐4800 DNA vaccine https://www.sciencedir EClinicalMedici Safety and immunogenicity of INO‐ 24‐Dec‐20 against SARS‐CoV‐2: A preliminary report of an open‐ Phase I vaccine trial USA/UK Tebas et al. ect.com/science/article/ NCT04336410 INO‐4800 DNA vaccine ne 4800 vaccine label, Phase 1 clinical trial pii/S2589537020304338

Phase 1/2 trial of SARSCoV‐2 vaccine ChAdOx1 nCoV‐19 https://www.nature.co Safety and exploratory humoral and ChAdOx1 nCoV‐19 17‐Dec‐20 Nature Med. with a booster dose induces multifunctional antibody Phase I/II vaccine trial UK Barrett J.R., et al. m/articles/s41591‐020‐ NCT04400838 cellular immunogenicity of the vaccine AZD1222 responses 01179‐4 AZD1222 vaccine

REGN‐COV2, a Interim study results: effects of high REGN‐COV2, a Neutralizing viral loads with complications Neutralizing Antibody REGN‐COV2 antibody 17‐Dec‐20 NEJM Antibody Cocktail, in RCT USA Weinreich D.M NCT04425629 and death from coronavirus disease Cocktail, in Outpatients cocktail Outpatients with Covid‐19 2019 (Covid‐19)‐REGN‐COV2 with Covid‐19 | NEJM effects on outpatients

Safety and immunogenicity clinical trial of an inactivated https://www.medrxiv.or To test the immunogenicity and safety SARS‐CoV‐2 vaccine, BBV152 (a phase 2, double‐blind, inactivated SARS‐CoV‐2 22‐Dec‐20 preprint ‐ BMJ Phase I/II vaccine trial India Raches et al. g/content/10.1101/2020 NCT04471519 of BBV152: 3 µg and 6 µg with Algel‐ randomised controlled trial) and the persistence of vaccine, BBV152 IMDG. immune responses from a phase 1 follow‐up report .12.21.20248643v1

A Neutralizing To test the effect of this antibody in A Neutralizing Monoclonal Antibody for Hospitalized ACTIV‐3/TICO LY‐ Monoclonal Antibody 22‐Dec‐20 NEJM RCT Denmark NCT04501978 LY‐CoV555 patients who are hospitalized with Patients with Covid‐19 CoV555 Study Group for Hospitalized Patients Covid‐19. with Covid‐19 | NEJM To test the effect of Tocilizumab on Efficacy of Tocilizumab in Efficacy of Tocilizumab multi‐organ dysfunction in a phase 3 10‐Dec‐20 NEJM Patients Hospitalized with RCT USA Stone J.H., et al in Patients Hospitalized NCT04356937 tocilizumab randomized controlled trial among Covid‐19 with Covid‐19 | NEJM hospitalized patients with COVID‐19 infection.

https://bmcinfectdis.bio Effect of Arbidol (Umifenovir) on COVID‐19: a medcentral.com/articles IRCT2018072504 To determine the effect of Arbidol 14‐Dec‐20 BMC Infect Dis RCT Iran Marzieh et al. Arbidol (Umifenovir) randomized controlled trial. /10.1186/s12879‐020‐ 0596N2 (ARB) on COVID‐19 disease. 05698‐w

https://trialsjournal.bio Interferon ß‐1a (IFNß‐1a) in COVID‐19 patients EudraCT 2020‐ To test the efficacy of Interferon‐β‐1a medcentral.com/articles Interferon ß‐1a (IFNß‐ 23‐Dec‐20 Trials (INTERCOP): study protocol for a randomized controlled RCT Italy Bosi et al. 002458‐25, (IFNβ‐1a), in COVID‐19 patients in an /10.1186/s13063‐020‐ 1a) trial. NCT04449380 open label, randomized clinical trial. 04864‐4

To evaluate the efficacy and safety of Safety and Efficacy of BNT162b2 is a lipid Safety and Efficacy of the BNT162b2 mRNA Covid‐19 the BNT162b2 mRNA NCT04368728. nanoparticle–formulated, nucleoside‐ 10‐Dec‐20 NEJM phase II vaccine trial USA Polack F.P., et al. BNT162b2 vaccine Vaccine Covid‐19 Vaccine | opens in new tab modified RNA vaccine that encodes a NEJM prefusion stabilized, membraneanchored SARS‐CoV‐2 https://academic.oup.co Journal of Sofosbuvir and daclatasvir for the treatment of COVID‐ m/jac/advance‐ IRCT2020040304 Is sofosbuvir/daclatasvir effective in 18‐Dec‐20 Antimicrobial 19 outpatients: a double‐blind, randomized controlled RCT Iran Roozbeh et al. article/doi/10.1093/jac/ sofosbuvir, daclatasvir 6926N1 COVID‐19 patiets? Chemotherapy trial dkaa501/6041772?login =true https://journals.lww.co m/ccejournal/Fulltext/2 Intravenous Immunoglobulin Plus Methylprednisolone To asses the efficacy and safety of IV 16 November Critical Care George Sakoulas, et 020/11000/Intravenous_ Mitigate Respiratory Morbidity in Coronavirus Disease RCT USA NCT04411667 Immunoglobulins immunoglobulin in hospitalized COVID‐ 2020 Explorations al. Immunoglobulin_Plus_ 2019 19 patients. Methylprednisolone.14. aspx

To evaluate the effect of combining Biological https://link.springer.co 23 November Do Zinc Supplements Enhance the Clinical Efficacy of Sherief Abd‐Elsalam, Zinc, chloroquine/hydroxychloroquine and Trace Element RCT Egypt m/article/10.1007/s1201 NCT04447534 2020 Hydroxychloroquine?: a Randomized, Multicenter Trial et al. Hydroxychloroquine zinc in the treatment of COVID‐19 Research 1‐020‐02512‐1 patients.

Effect of Vitamin D3 Supplementation vs Placebo on https://www.medrxiv.or To determine if vitamin D3 Hospital Length of Stay in Patients with Severe COVID‐ g/content/10.1101/2020 supplementation can reduce hospital 17‐Nov MedRxiv RCT Brazil Murai et al. NCT04449718 Vitamin D3 19: A Multicenter, Double‐blind, Randomized 3 .11.16.20232397v1.full.p length of stay in hospitalized patients Controlled Trial df with severe COVID‐19?

To determine whether a single, 180 https://www.medrxiv.or mcg subcutaneous dose of Peginterferon Lambda‐1a for treatment of outpatients g/content/10.1101/2020 Peginterferon Lambda‐ Peginterferon Lambda‐1a (Lambda) 23‐Nov MedRxiv with uncomplicated COVID‐19: a randomized placebo‐ RCT USA Jagannathan et al. NCT04331899 .11.18.20234161v1.full.p 1a could shorten the duration of viral controlled trial df shedding or symptoms in patients with mild to moderate COVID‐19.

https://www.medrxiv.or To evaluate the efficacy of convalescent plasma with high titers of Prevention of severe COVID‐19 in the elderly by early g/content/10.1101/2020 21‐Nov MedRxiv RCT Argentina Libster et al. NCT04479163 Convalescent plasma SARS‐CoV2 antibody administered hightiter plasma .11.20.20234013v1.full.p within 72 hours of mild symptoms to df elderly patients with Covid‐19 To estimate the efficacy and safety of A two‐arm, randomized, controlled, multi‐centric, open‐ https://www.medrxiv.or Itolizumab in the treatment of cytokine label Phase‐2 study to evaluate the efficacy and safety of g/content/10.1101/2020 CTRI/2020/05/02 release syndrome in patients with 02‐Dec MedRxiv RCT India Kumar et al. Itolizumab Itolizumab in moderate to severe ARDS patients due to .12.01.20239574v1.full.p 4959 moderate to severe acute respiratory COVID‐19 df distress syndrome (ARDS) due to COVID‐19.

5‐Alpha‐Reductase Inhibitors Reduce Remission Time of https://www.medrxiv.or To determine if 5‐alpha‐reductase COVID‐19: Results From a Randomized Double Blind g/content/10.1101/2020 inhibitors (5ARis) are a beneficial 18‐Nov MedRxiv RCT Brazil, USA Cadegiani et al. NCT04446429 Dutasteride Placebo Controlled Interventional Trial in 130 SARSCoV‐2 .11.16.20232512v1.full.p treatment for COVID‐19 if given after Positive Men df SARS‐CoV‐2 infection

https://reader.elsevier.c To test the effect Pentoxifylline (PTX) om/reader/sd/pii/S1567 on parameters such as LDH, International Pentoxifylline decreases serum LDH levels and increases 576920336766?token=E lymphocyte count, days of 11‐Nov Immunopharm lymphocyte count in COVID‐19 patients: Results from an RCT Mexico Maldonado et al. COF‐002495 Pentoxifylline DD4B561C8D7F700793B hospitalization, mortality, and the need acology external pilot study 55AFFA9EE8F0CD28010 for intubation on patients with severe BE3E0CADC0EF90237E4 and moderate COVID‐19

hydroxychloroquine, https://www.nejm.org/ Repurposed Antiviral Drugs for Covid‐19 — Interim WHO WHO Solidarity Trial ISRCTN83971151, lopinavir/ritonavir, 02‐Dec‐20 NEJM RCT Multinational doi/10.1056/NEJMoa202 effects of drugs on in‐hospital mortality Solidarity Trial Results Consortium NCT04315948 interferon beta1, 3184 remdesivir

https://www.nejm.org/ Does postexposure prophylaxis with A Cluster‐Randomized Trial of Hydroxychloroquine for 24‐Nov‐20 NEJM RCT Spain Mitjà et al. doi/10.1056/NEJMoa202 NCT04304053 Hydroxychloroquine hydroxychloroquine prevent SARS‐CoV‐ Prevention of Covid‐19 1801 2 infection?

https://www.nejm.org/ Is treatment with convalescent plasma A Randomized Trial of Convalescent Plasma in Covid‐19 24‐Nov‐20 NEJM RCT Argentina Simonovich et al. doi/10.1056/NEJMoa203 NCT04383535 Convalescent plasma associated with improved clinical Severe Pneumonia 1304 outcomes in COVID‐19 patients?

Safety and immunogenicity of ChAdOx1 nCoV‐19 vaccine https://www.sciencedir Safety and immunogenicity of administered in a prime‐boost regimen in young and old phase II/III vaccine ect.com/science/article/ NCT04400838, 19‐Nov‐20 The Lancet UK Ramasamy et al. ChAdOx1 vaccine ChAdOx1 vaccine in young and old adults (COV002): a single‐blind, randomised, controlled, trial pii/S0140673620324661 ISRCTN 15281137 adults phase 2/3 trial ?via%3Dihub

Safety, tolerability, and immunogenicity of an inactivated https://www.sciencedir Lancet Infect. SARS‐CoV‐2 vaccine in healthy adults aged 18–59 years: ect.com/science/article/ Safety, tolerability and immunogenicity 18‐Nov‐20 I/II vaccine trial China Zhang et al. NCT04352608 CoronaVac vaccine Dis. a randomised, double‐blind, placebo‐controlled, phase pii/S1473309920308434 of CoronaVac vaccine 1/2 clinical trial. ?via%3Dihub

https://www.medrxiv.or Randomized controlled trial of convalescent plasma Pilot study designed to inform the Bahrain, g/content/10.1101/2020 04‐Nov MedRxiv therapy against standard therapy in 2 patients with RCT Al Qahtani et al. NCT04356534 Convalescent plasma design of a definitive phase 3 clinical Ireland .11.02.20224303v1.full.p severe COVID‐19 disease trial. df

https://www.medrxiv.or To evaluate a single subcutaneous Peginterferon‐lambda for the treatment of COVID‐19 in g/content/10.1101/2020 12/11/2020 MedRxiv RCT Canada Feld et al. NCT04354259 Peginterferon injection of peginterferon‐lambda in outpatients .11.09.20228098v1.full.p outpatients with COVID‐19. df https://reader.elsevier.c om/reader/sd/pii/S1567 International Evaluating the effects of Intravenous Immunoglobulin To investigate the potential usefulness 576920336729?token=1 IRCT2015122702 Intravenous 13‐Nov Immunopharm (IVIg) on the management of severe COVID‐19 cases: A RCT Iran Tabarsi et al. of IVIg for the management of severe 3C23CAB7F2F51222936F 5726N20 Immunoglobulin acology randomized controlled trial cases of Covid‐19. 6967643ECEC50F680C6C 1B600298B1211225F0D To evaluate the therapeutic International Randomized Controlled Open Label Trial on the Use of https://www.sciencedir effectiveness of favipiravir combined 9 November Journal of Favipiravir Combined with Inhaled Interferon beta‐1b in ect.com/science/article/ Favipiravir, interferon RCT Oman Faryal Khamis, et al. NA with inhaled interferon beta‐1b in adult 2020 (preprint) Infectious Hospitalized Patients with Moderate to Severe COVID‐19 pii/S1201971220323195 beta‐1b patients hospitalized with moderate to Diseases Pneumonia ?via%3Dihub severe COVID‐19 pneumonia.

https://academic.oup.co Clinical Randomized, double‐blinded and placebo‐controlled m/cid/advance‐ Assess the safety and immunogenitcity Preprint Infectious phase II trial of an inactivated SARS‐CoV‐2 vaccine in Phase 2 vaccine trial China Yanchun Che, et al. NCT04412538 Inactivated vaccine article/doi/10.1093/cid/ of this inactiviated vaccine Diseases healthy adults ciaa1703/5962856

To evaluate the efficacy of PEP with International https://www.sciencedir Post‐exposure prophylaxis with hydroxychloroquine for HCQ for the prevention of COVID‐19 in 6 November Journal of Deba Prasad Dhibar, ect.com/science/article/ the prevention of COVID‐19, a myth or a reality? The PEP RCT India NCT04408456 Hydroxychloroquine asymptomatic non‐HCW in‐ dividuals 2020 (in press) Antimicrobial et al. pii/S0924857920304350 CQ Study who were at risk for SARS‐CoV‐2 Agents ?via%3Dihub infection

To assess the safety, tolerability, and https://www.medrxiv.or immunogenicity of CoVLP at three dose Phase 1 trial of a Candidate Recombinant Virus‐Like Preprint MedRxiv Phase 1 vaccine Trial Canada Brian J Ward, et al. g/content/10.1101/2020 NCT04450004 CoVLP vaccine levels unadjuvanted or adjuvanted Particle Vaccine for Covid‐19 Disease Produced in Plants .11.04.20226282v1 with either CpG 1018 or AS03 in healthy adults 18 to 55 years of age.

https://www.sciencedir E‐Clinical An open‐label, randomized trial of the combination of To evaluate the efficacy and safety in ect.com/science/article/ ChiCTR20000302 27 October 2020 Medicine IFN‐κ plus TFF2 with standard care in the treatment of RCT China Weihui Fu, et al. IFN‐κ plus TFF2 patients with moderate COVID‐19 f the pii/S2589537020302911 62 (Lancet) patients with moderate COVID‐19 combination of IFN‐κ plus TFF2 ?via%3Dihub

https://www.thelancet.c Safety and efficacy of inhaled nebulised interferon beta‐ The Lancet om/journals/lanres/artic 1a (SNG001) for treatment of SARS‐CoV‐2 infection: a 2020‐001023‐14, Efficacy and safety of inhaled nebulised 12‐Nov‐20 Respiratory RCT UK Monk et al. le/PIIS2213‐ INF‐beta 1a randomised, double‐blind, placebo‐controlled, phase 2 NCT04385095 interferon beta‐1a Medicine trial 2600(20)30511‐ 7/fulltext

Determine whether fluvoxamine, given Fluvoxamine vs Placebo and Clinical Deterioration in https://jamanetwork.co during mild COVID‐19 illness, prevents 12‐Nov‐20 JAMA Outpatients With Symptomatic COVID‐19A Randomized RCT USA Lenze et al. m/journals/jama/article‐ NCT04342663 Fluvoxamine clinical deterioration and decreases the Clinical Trial abstract/2773108 severity of disease

Antiviral effect of high‐dose ivermectin in adults with https://papers.ssrn.com Preprint The Lancet COVID‐19: a pilot randomised, controlled, open label, RCT Argentina Krolewiecki et al. /sol3/papers.cfm?abstra NCT004381884 Ivermectin Does ivermectin reduce the viral load? multicentre trial ct_id=3714649

https://www.medrxiv.or To compare the efficacy and safety of Efficacy of Convalescent Plasma Therapy compared to g/content/10.1101/2020 convalescent plasma with fresh frozen 27‐Oct MedRxiv Fresh Frozen Plasma in Severely ill COVID‐19 Patients: A RCT India Bajpai et al. NCT04346446 Convalescent plasma .10.25.20219337v1.full.p plasma (FFP) in severe COVID‐19 Pilot Randomized Controlled Trial. df patients

https://www.medrxiv.or To evaluate the efficacy and safety of A placebo‐controlled double blind trial of Dubée et al. for the g/content/10.1101/2020 hydroxychloroquine in adult patients 21‐Oct MedRxiv RCT France NCT04325893 Hydroxychloroquine hydroxychloroquine in mild‐to‐moderate COVID‐19 HYCOVID study group .10.19.20214940v1.full.p with mild‐to‐moderate COVID‐19 at df risk of worsening.

https://www.medrxiv.or To evaluate whether early nitazoxanide Early use of nitazoxanide in mild Covid‐19 disease: g/content/10.1101/2020 therapy would be effective in 23‐Oct MedRxiv RCT Brazil Rocco et al. NCT04552483 Nitazoxanide randomized, placebo controlled trial .10.21.20217208v1.full.p accelerating symptom resolution in df patients with mild COVID‐19.

https://www.medrxiv.or To test the combinational therapy of Controlled randomized clinical trial on using Ivermectin g/content/10.1101/2020 Ivermectin + Ivermectin and Doxycycline in treating 27‐Oct MedRxiv with Doxycycline for treating COVID‐19 patients in RCT Iraq Hashim et al. NCT04591600 .10.26.20219345v1.full.p Doxycycline COVID‐19 patients at different stages of Baghdad, Iraq df the disease.

Treatment with human umbilical cord‐derived https://www.medrxiv.or To assess the efficacy and safety of human umbilical cord‐ mesenchymal stem cells for COVID‐19 patients with lung g/content/10.1101/2020 human umbilical cord‐mesenchymal 21‐Oct MedRxiv RCT China Shi et el. NCT04288102 derived mesenchymal damage: a randomised, double‐blind, placebo‐controlled .10.15.20213553v2.full.p stem cells (UC‐MSCs) to treat severe stem cells phase 2 trial df COVID‐19 patients with lung damage.

Umbilical Cord Mesenchymal Stem Cells for COVID‐19 https://papers.ssrn.com human umbilical cord‐ To determine safety and explore Lancet pre‐ 26‐Oct ARDS: A Double Blind, Phase 1/2a, Randomized RCT USA Lanzoni et al. /sol3/papers.cfm?abstra NCT04355728 derived mesenchymal efficacy of Umbilical Cord (UC)‐MSC print Controlled Trial ct_id=3696875 stem cells infusions in COVID‐19 ARDS.

https://academic.oup.co To determine whether J Antimicrob Sofosbuvir/daclatasvir regimens for the treatment of m/jac/advance‐ sofosbuvir/daclatasvir‐based regimens 01‐Nov Meta‐analysis UK/Iran Simmons et al. N/A sofosbuvir/daclatasvir Chemother COVID‐19: an individual patient data meta‐analysis article/doi/10.1093/jac/ improve clinical outcomes of patients dkaa418/5924537 with moderate or severe COVID‐19.

https://papers.ssrn.com To evaluate the efficacy and safety of Lancet pre‐ Phase 3 Trial of Coronavir (Favipiravir) in Patients with 26‐Oct RCT Russia Ruzhentsova et al. /sol3/papers.cfm?abstra NCT04501783 Favipiravir favipiravir for treatment of mild to print Mild to Moderate COVID‐19 ct_id=3696907 moderate COVID‐19

Imunopatholog https://www.sciencedir Treatment of Coronavirus Disease 2019 Patients with Efficacy of COVID‐19 convalescent y and ect.com/science/article/ 01‐Nov‐20 Convalescent Plasma Reveals a Signal of Significantly RCT USA Salazar et al. Convalescent plasma plasma transfusion for severe and/or infectious pii/S0002944020303709 Decreased Mortality critical COVID‐19. diseases ?via%3Dihub

https://www.nejm.org/ Efficacy of Tocilizumab in Patients Hospitalized with Does tocilizumab prevent intubation or 21‐Oct‐20 NEJM RCT USA Stone et al. doi/pdf/10.1056/NEJMo NCT04356937 Tocilizumab Covid‐19 death? a2028836

https://jamanetwork.co To determine whether tocilizumab Effect of Tocilizumab vs Usual Care in Adults Hospitalized JAMA Internal m/journals/jamainternal (TCZ) improves outcomes of patients 20‐Oct‐20 With COVID‐19 and Moderate or Severe Pneumonia: A RCT France Hermine et al. NCT04331808 Tocilizumab Medicine medicine/fullarticle/277 hospitalized with moderate‐to‐severe Randomized Clinical Trial 2187 COVID‐19 pneumonia

https://jamanetwork.co NCT04346355; Effect of Tocilizumab vs Standard Care on Clinical JAMA Internal m/journals/jamainternal EudraCT To evaluate the effect of early 20‐Oct‐20 Worsening in Patients Hospitalized With COVID‐19 RCT Italy Salvarani et al. Tocilizumab Medicine medicine/fullarticle/277 Identifier: 2020‐ tocilizumab administration PneumoniaA Randomized Clinical Trial 2186 001386‐37.

International Journal of https://pharmascope.or To evaluate the efficacy of umifenovir Efficacy of umifenovir in the treatment of mild and Randomized clinical 01‐Oct‐20 Research in Kyrgizstan Yethindra et al. g/ijrps/article/view/283 NA Umifenovir in mild and moderate COVID‐19 moderate covid‐19 patients study Pharmaceutical 9/6116 patients Sciences https://www.nejm.org/ To evaluate the efficacy of remdesivir 8 October 2020 NEJM Remdesivir for the Treatment of Covid‐19 — Final Repor RCT USA John H. Beigel, et al. doi/10.1056/NEJMoa200 NCT04280705 Remdesivir in shortening time to recovery in 7764 hospitalized COVID‐19 patients.

https://www.sciencedir Safety and immunogenicity of an inactivated SARS‐CoV‐2 To assess the safety and ect.com/science/article/ ChiCTR20000324 15 October 2020 Lancet vaccine, BBIBP‐CorV: a randomised, double‐blind, Phase 1/2 vaccine trial China Shengli Xia, et al. BBIBP‐CorV immunogenicity of an inactivated SARS pii/S1473309920308318 59. placebo‐controlled, phase 1/2 trial CoV2 vaccine ?via%3Dihub

Lopinavir/ritonavir, https://www.medrxiv.or Repurposed antiviral drugs for COVID‐19 remdesivir, Are repurposed andiviral drugs 15 October 2020 MedRiXV RCT International Hongchao Pan, et al. g/content/10.1101/2020 ISRCTN83971151 –interim WHO SOLIDARITY trial results hydroxychloroquine, effective in treating COV ID19? .10.15.20209817v1 interferon

To assess the safety and dose response https://www.nejm.org/ through reduction of viral load of SARS‐CoV‐2 Neutralizing Antibody LY‐CoV555 in Monoclonal antibody, 28 October 2020 NEJM Phase 2 RCT USA Peter Chen, et al. doi/10.1056/NEJMoa202 NCT04427501 monoclonal antibody LY‐CoV555 in Outpatients with Covid‐19 LY‐CoV555 9849 patients with mild or moderate COVID‐ 19 To assess if a simple incentive to self https://papers.ssrn.com prone for a maximum of 12 h per day Self‐Proning in COVID‐19 Patients on Low‐Flow Oxygen would decrease oxygen needs in 21 October 2020 Lancet preprint RCT Switzerland Aileen Kharat, et al. /sol3/papers.cfm?abstra SNCTP000003718 Self‐proning Therapy: A Cluster Randomised Controlled Trial patients admitted for COVID‐19 ct_id=3692538 pneumonia on low‐flow oxygen therapy.

International Interim analysis of an open‐label randomized controlled https://onlinelibrary.wil To assess if nasal irrigation can reduce 11 September Forum of trial evaluating nasal irrigations in non‐hospitalized RCT USA Kyle S. Kimura, et al. ey.com/doi/10.1002/alr. NA Nasal irrigations symptoms and viral shedding in mild 2020 Allergy and patients with coronavirus disease 2019 and moderate COVID‐19 patients Rhinology 22703

To assess the safety and efficacy of https://www.medrxiv.or Tocilizumab in nonventilated patients hospitalized with tocilizumab in patients hospitalized and Preprint MedRiXV RCT USA Carlos Salama, et al. g/content/10.1101/2020 NCT04372186 Tocilizumab Covid‐19 pneumonia non‐ventilated with Covid‐19 .10.21.20210203v1 pneumonia.

https://bmcinfectdis.bio The use of intravenous immunoglobulin gamma for the To evaluate the efficacy of intravenous BMC Infectious Naser Gharebaghi, et medcentral.com/articles IRCT2020050104 Immunoglobulin 21 October 2020 treatment of severe coronavirus disease 2019: a RCT Iran immunoglobulin (IVIg) in patients with Diseases al. /10.1186/s12879‐020‐ 7259N1 gamma randomized placebo‐controlled double‐blind clinical trial severe COVID‐19 infection. 05507‐4

Anti‐C5a antibody IFX‐1 (vilobelimab) treatment versus https://www.thelancet.c Phase 2 study to explore the potential 28 September best supportive care for patients with severe COVID‐19 Alexander P J Vlaar, om/action/showPdf?pii= benefit and safety of IFX‐1 Lancet RCT Netherlands NCT04333420 Vilobelimab 2020 (PANAMO): an exploratory, open‐label, phase 2 et al. S2665‐ (vilobelimab) in patients with severe randomised controlled trial 9913%2820%2930341‐6 COVID‐19.

https://www.nejm.org/ Is the SARS CoV‐2 mRNA 1273 safe and 29 September Safety and Immunogenicity of SARS‐CoV‐2 mRNA‐1273 Evan J. Anderson, et NEJM Vaccine trial Phase 1 USA doi/full/10.1056/NEJMo NCT04283461 mRNA‐1273 vaccine well tolerated in older adults and does 2020 Vaccine in Older Adults al. a2028436 it ellicit an immune response?

30 September https://www.nature.co Does the BNT162b1 vaccine elicit both COVID‐19 vaccine BNT162b1 elicits human antibody and Vaccine trial Phase 1 2020 ‐pre‐ Nature Germany Ugur Sahin, et al. m/articles/s41586‐020‐ NCT04380701 BNT162b1 vaccine antibody and T‐cell response in healthy TH1 T‐cell responses and 2 approved 2814‐7 adults?

https://assets.researchs To evaluate the efficacy and safety of quare.com/files/rs‐ recombinant super‐compound Research Engineered interferon alpha effectively improves clinical ChiCTR20000296 Engineered interferon Preprint RCT China Chuan Li, et al. 65224/v1/22886bf0‐ interferon versus traditional interferon Square outcomes of COVID‐19 patients 38 alpha ce06‐4d42‐aeb6‐ alpha in patients with moderate to c73ebb7c2003.pdf severe COVID‐19

https://www.sciencedir International To evaluate the efficacy and safety of Interferonβ‐1b in treatment of severe COVID‐19: A Hamid Rahmani, et ect.com/science/article/ IRCT2010022800 24 August 2020 Immunopharm RCT Iran Interferon β‐1b interferon (IFN) β‐1b in the treatment randomized clinical trial al. pii/S1567576920323304 3449N27 acology of patients with severe COVID‐19 ?via%3Dihub

To evaluate the efficacy of https://jamanetwork.co hydroxychloroquine to prevent Efficacy and Safety of Hydroxychloroquine vs Placebo for 30 September Benjamin S Abella, et m/journals/jamainternal transmission of SARS‐CoV‐2 in hospital‐ JAMA Pre‐exposure SARS‐CoV‐2 Prophylaxis Among Health RCT USA NCT04329923 Hydroxychloroquine 2020 al. medicine/fullarticle/277 based HCWs with exposure to patients Care Workers 1265 with COVID‐19 using a pre‐exposure prophylaxis strategy

Drug treatments for covid‐19: living systematic review To compare the effects of treatments 4 September International Reed AC Siemieniuk, https://www.bmj.com/c BMJ and Systematic review NA All treatments for coronavirus 2020 collaboration et al. ontent/370/bmj.m2980 network meta‐analysis disease 2019 (covid‐19).

To compare the rate of clinical https://www.ncbi.nlm.ni improvement among patients with Effect of remdesivir on patients with COVID‐19: A 15‐Oct Virus Research Meta‐analysis USA, Japan Yokoyama et al. h.gov/pmc/articles/PMC N/A Remdesivir COVID‐19 who received 5‐day course network meta‐analysis of randomized control trials 7437510/pdf/main.pdf of remdesivir versus 10‐day course of remdesivir versus standard care. To investigate the safety and https://www.medrxiv.or immunogenicity of an inactivated viral An in‐depth investigation of the safety and g/content/10.1101/2020 vaccine in immunized individuals in a 06‐Sep MedRxiv Phase 1 RCT China Pu et el. NCT04412538 Vaccine immunogenicity of an inactivated 2 SARS‐CoV‐2 vaccine .09.27.20189548v1.full.p phase I trial, especially focusing on df safety with regard to the immunopathology of the vaccine.

https://www.medrxiv.or Clearing the fog: Is Hydroxychloroquine effective in To assess the efficacy of HCQ in Mehmood Kamran et g/content/10.1101/2020 11‐Oct MedRxiv reducing Corona virus disease‐2019 progression: A RCT Pakistan NCT04491994 Hydroxychloroquine reducing disease progression in mild al. .07.30.20165365v2.full.p randomized controlled trial COVID‐19 df

https://www.thelancet.c Lopinavir–ritonavir in patients admitted to hospital with ISRCTN Whether lopinavir–ritonavir improves Horby et al. om/action/showPdf?pii= 05‐Oct‐20 The Lancet COVID‐19 (RECOVERY): a randomised, controlled, open‐ RCT UK 50189673, lopinavir/ritonavir outcomes in patients admitted to (RECOVERY GROUP) S0140‐ label, platform trial NCT04381936 hospital with COVID‐19 6736%2820%2932013‐4

https://www.sciencedir An open‐label, randomized trial of the combination of EClinicalMedici ect.com/science/article/ ChiCTR20000302 Efficacy and safety of IFN‐κ and TFF2 in 20‐Sep‐20 IFN‐kappa plus TFF2 with standard care in the treatment RCT China Fu et al. IFN‐κ , TFF2 ne pii/S2589537020302911 62 COVID patients. of patients with moderate COVID‐19 ?via%3Dihub

Vaccine: non‐replicating https://www.medrxiv.or adenovirus 26 based Safety and immunogenicity of the Ad26.COV2.S COVID‐ To evaluate the efficacy of a single Netherlands, g/content/10.1101/2020 vector expressing the 25‐Sep MedRxiv 19 vaccine candidate: interim results of a phase 1/2a, Phase 1/2a RCT Sadoff et al. NCT04436276 vaccination of 5x1010 vp of Belgium, USA .09.23.20199604v1.full.p stabilized pre‐fusion double‐blind, randomized, placebo‐controlled trial Ad26.COV2.S df spike protein of SARS‐ CoV‐2 https://www.medrxiv.or To determine the effectiveness of Hydroxychloroquine as pre‐exposure prophylaxis for g/content/10.1101/2020 hydroxychloroquine as pre‐exposure 21‐Sep MedRxiv RCT USA Rajasingham et al. NCT04328467 Hydroxychloroquine COVID‐19 in healthcare workers: a randomized trial .09.18.20197327v1.full.p prophylaxis in healthcare workers at df high‐risk of SARS‐CoV‐2 exposure

https://www.medrxiv.or Treatment with an Anti‐CK2 Synthetic Peptide Improves IG/CIGB300I/CV/ To explore safety and efficacy of CIGB‐ g/content/10.1101/2020 Anti‐CK2 Synthetic 22‐Sep MedRxiv Clinical 3 Response in Covid‐19 Patients with Pneumonia. RCT Cuba Cruz et al. 2001, ATENEA‐Co‐ 325, an anti‐CK2 peptide, in COVID‐19 .09.03.20187112v2.full.p Peptide, CIGB‐325 A Randomized and 4 Controlled Clinical Trial 300 trial patients. df

https://www.sciencedir To compare the rate of clinical improvement among patients with Effect of remdesivir on patients with COVID‐19: A Yujiro Yokoyama et ect.com/science/article/ 15‐Oct Virus Research Meta‐analysis USA, Japan N/A Remdesivir COVID‐19 who received 5‐day course network meta‐analysis of randomized control trials al. pii/S0168170220310443 of remdesivir versus 10‐day course of ?via%3Dihub remdesivir versus standard care.

https://academic.oup.co Clinical Remdesivir for Severe COVID‐19 versus a Cohort Susan A. Olender, et m/cid/advance‐ NCT04292899 Efficacy of remdesivir in COVID19 24 July 2020 Infectious RCT vs cohort USA Remdesivir Receiving Standard of Care al. article/doi/10.1093/cid/ and EUPAS34303 patients Diseases ciaa1041/5876045

Assess the efficacy of favipiravir in Antimicrobial A prospective, randomized, open‐label trial of early https://aac.asm.org/con 17 November asymptomatic or mild COVID19 Agents versus late favipiravir in hospitalized patients with COVID RCT Japan Yohei Doi, et al. tent/early/2020/09/16/ jRCTs041190120 Favipiravir 2020 patients in viral clearance, and Chemotherapy 19 AAC.01897‐20 resolution of symptoms

https://virologyj.biomed Favipiravir versus other antiviral or standard of care for To evaluate the efcacy and safety of Virology Systematic review & Dhan Bahadur central.com/articles/10. 24‐Sep COVID‐19 treatment: a rapid systematic review and Nepal N/A Favipiravir the drug Favipiravir as a treatment for Journal meta‐analysis Shrestha et al. 1186/s12985‐020‐01412‐ meta‐analysis COVID‐19. z

https://www.thrombosi To compare therapeutic enoxaparin Therapeutic versus prophylactic anticoagulation for 20 September Thrombosis Anna Cristina Bertoldi sresearch.com/article/S REBEC RBR‐ Enoxaparin, treatment to standard prophylactic severe COVID‐19: A randomized phase II clinical trial RCT Brazil 2020 Research Lemos, et al. 0049‐3848(20)30530‐ 949z6v anticoagulants anticoagulant treatment in severe (HESACOVID) 2/fulltext#%20 COVID19

https://academic.oup.co To evaluate the efficacy and safety of Clinical Treatment of COVID‐19 Patients with Prolonged Post‐ m/cid/advance‐ ChiCTR leflunomide to treat COVID‐19 patients Preprint Infectious Symptomatic Viral Shedding with Leflunomide ‐‐ a Single‐ RCT China Wang, et al Leflunomide article/doi/10.1093/cid/ 2000030058 with prolonged post‐symptomatic viral Diseases Center, Randomized, Controlled Clinical Trial ciaa1417/5909448 shedding.

https://www.clinicalmicr Effect of hydroxychloroquine with or without To assess the effect of chloroquine and Clinical obiologyandinfection.co Chloroquine, azithromycin on the mortality of coronavirus disease Systematic Review France, hydroxychloroquine with or without 26 August 2020 Microbiology Thibault Fiolet, et al. m/article/S1198‐ NA hydroxychloroquine, 2019 (COVID‐19) patients: a systematic review and meta‐ and Meta‐analysis Switzerland azithromycin on the mortality of COVID‐ and Infection azithromycin analysis 743X(20)30505‐ 19 patients X/fulltext

To evaluate and compare different https://www.medrxiv.or Efficacy of commercial mouth‐rinses on SARS‐CoV‐2 viral Chaminda Jayampath commercial moutwash solutions and Preprint MedRxIV RCT Singapore g/content/10.1101/2020 NA Mouth wash load in saliva: Randomized Control Trial in Singapore Seneviratne, et al. their effect on reducing salivary viral .09.14.20186494v1 load

Early Anti‐SARS‐CoV‐2 Convalescent Plasma in Patients https://www.medrxiv.or Evaluate the safety and efficacy of María Elvira Balcells, Preprint MedRxIV Admitted for COVID‐19: A Randomized Phase II Clinical RCT Chile g/content/10.1101/2020 NCT04375098 Covalescent Plasma convalescent plasma and compare an et al. Trial .09.17.20196212v1 early vs deferred treatement strategy

Evaluate the efficacy of bromhexine in Effect of bromhexine on clinical outcomes and mortality https://bi.tbzmed.ac.ir/ IRCT2020031170 intensive care unit (ICU) admission, 19 July 2020 Bioimpacts RCT Iran Khalil Ansarin Bromhexine in COVID‐19 patients: A randomized clinical trial Article/bi‐23240 46797N4 mechanical ventilation, and mortality in patients with COVID‐19.

Expert Review https://www.tandfonlin Identify studies pertaining to antivirals of Anti‐ e.com/doi/abs/10.1080/ 12‐Sep‐20 The effect of antivirals on COVID‐19: a systematic review Systematic review Hussain et al. UK NA Antivirals in COVID‐19 patients and review the Infective 14787210.2021.1823832 clinical outcomes Therapy ?journalCode=ierz20

https://academic.oup.co Clinical Double‐blind, randomized, placebo‐controlled trial with To determine whether NAC in high 23 September Julio Cesar Garcia de m/cid/advance‐ Infectious N‐acetylcysteine for treatment of severe acute RCT Brazil doses can avoid respiratory failure in 2020 Alencar, et al. article/doi/10.1093/cid/ Diseases respiratory syndrome caused by COVID‐19 patients with Covid‐19. ciaa1443/5910353

https://erj.ersjournals.c European Intravenous methylprednisolone pulse as a treatment for om/content/early/2020/ IRCT2020040404 Is methylprednisolone effective in 17‐Sep‐20 Respiratory hospitalised severe COVID‐19 patients: results from a RCT Iran Edalatifard et al. Methylprednisolone 09/09/13993003.02808‐ 6947N1 treatment of COVID‐19 patients? Journal randomised controlled clinical trial 2020

https://journals.plos.org Interventions for treatment of COVID‐19: A living /plosmedicine/article?id Effects of all treatment interventions 17‐Sep‐20 Plos Medicine systematic review with meta‐analyses and trial Meta‐analysis Denmark Juul et al. NA NA =10.1371/journal.pmed. for COVID‐19 sequential analyses (The LIVING Project) 1003293

Safety and immunogenicity of an rAd26 and rAd5 vector‐ https://www.sciencedir NCT04436471 Safety and immunogenicity of two based heterologous prime‐boost COVID‐19 vaccine in ect.com/science/article/ 04‐Sep‐20 The Lancet CT Russia Logunov et al. and vaccine formulations (frozen and lyophilised) of two formulations: two open, non‐randomised phase 1/2 pii/S0140673620318663 NCT04437875 vaccine studies from Russia ?via%3Dihub

International https://www.sciencedir Can therapy with HCQ+AZM reduce the Journal of Safety and effectiveness of azithromycin in patients with ect.com/science/article/ 01‐Oct‐20 RCT Iran Sekhavati et al. NA azithromycine hospital length of stay in COVID‐19 Antimicrobial COVID‐19: An open‐label randomised trial pii/S0924857920303411 patients? Agents ?via%3Dihub

Effect of Recombinant Human Granulocyte https://jamanetwork.co Do increased peripheral blood Colony–Stimulating Factor for Patients With Coronavirus m/journals/jamainternal ChiCTR20000300 leukocyte and lymphocyte cell counts 10‐Sep‐20 JAMA RCT China Cheng et al. G‐CSF Disease 2019 (COVID‐19) and Lymphopenia: A medicine/fullarticle/277 07 lead to clinical improvement in patients Randomized Clinical Trial 0680 with COVID‐19?

Azithromycin in addition to standard of care versus https://www.thelancet.c standard of care alone in the treatment of patients om/action/showPdf?pii= Would azithromycine improve clinical 04‐Sep‐20 The Lancet RCT Brazil Furtado et al. NCT04321278 azithromycine admitted to the hospital with severe COVID‐19 in Brazil S0140‐ outcomes to COVID‐19 patiets? (COALITION II): a randomised clinical trial 6736%2820%2931862‐6

Is the use of CQ or HCQ effective and Journal https://link.springer.co safe in reducing mortality and Genenral Chloroquine and Hydroxychloroquine for the Treatment Arunmozhimaran Chloroquine, 03‐Sep‐20 Systematic review India m/article/10.1007/s1160 NA improving the clinical course, fever Internal of COVID‐19: a Systematic Review and Meta‐analysis Elavarasi, et al. hydroxychloroquine remission, and virologic clearance in Medicine 6‐020‐06146‐w COVID‐19 patients? Diabetes & Metabolic https://www.sciencedir No benefit of hydroxychloroquine in COVID‐19: Results November ‐ Syndrome: ect.com/science/article/ Is HCQ effective in milde to moderate of Systematic Review and Meta‐Analysis of Randomized Systematic review India Pathak et al. NA hydroxychloroquine December 2020 Clinical pii/S1871402120303362 COVID‐19 patients? Controlled Trials" Research & ?via%3Dihub Reviews

Naunyn‐ https://link.springer.co Schmiedeberg' Hydroxychloroquine use and progression or prognosis of Benefits and harms of HCQ in COVID‐ 06‐Sep‐20 Systematic review China Zang et al m/article/10.1007%2Fs0 NA hydroxychloroquine s Archives of COVID‐19: a systematic review and meta‐analysis 19 patients Pharmacology 0210‐020‐01964‐5

https://jamanetwork.co Effect of Dexamethasone on Days Alive and Ventilator‐ m/journals/jama/fullarti To determine whether intravenous Free in Patients With Moderate or Severe Acute Bruno M. Tomazini, cle/2770277?utm_camp dexamethasone increases the number 02‐Sep‐20 JAMA RCT Brazil NCT04327401 Dexamethasone Respiratory Distress Syndrome and COVID‐19 The CoDEX et al. aign=articlePDF&utm_m of ventilator‐free days among patients Randomized Clinical Trial edium=articlePDFlink&u with COVID‐19–associated ARDS. tm source=articlePDF& https://jamanetwork.co m/journals/jama/fullarti PROSPERO To estimate the association between Association Between Administration of Systemic International cle/2770279?utm_camp database administration of corticosteroids 02‐Sep‐20 JAMA Corticosteroids and Mortality Among Critically Ill Meta‐analysis Jonathan A.C., et al. Corticosteroids Collaboration aign=articlePDF&utm_m (CRD4202019724 compared with usual care or placebo Patients With COVID‐19 ‐ A Meta‐analysis edium=articlePDFlink&u 2) and 28‐day all‐cause mortality. tm source=articlePDF& https://jamanetwork.co m/journals/jama/fullarti Does low‐dose hydrocortisone Effect of Hydrocortisone on 21‐Day Mortality or Pierre‐François cle/2770276?utm_camp decrease treatment failure in patients 02‐Sep‐20 JAMA Respiratory Support Among Critically Ill Patients With RCT France NCT02517489 Hydrocortisone Dequin, et al. aign=articlePDF&utm_m with COVID‐19–related acute COVID‐19 ‐ A Randomized Clinical Trial edium=articlePDFlink&u respiratory failure? tm source=articlePDF& https://jamanetwork.co Effect of Hydrocortisone on Mortality and Organ m/journals/jama/fullarti To determine whether hydrocortisone Support in Patients With Severe COVID‐19 The REMAP‐ cle/2770278?utm_camp 02‐Sep‐20 JAMA RCT UK Derek C. Angus, et al. NCT02735707 Hydrocortisone improves outcome for patients CAP COVID‐19 Corticosteroid Domain Randomized aign=articlePDF&utm_m with severe COVID‐19. Clinical Trial edium=articlePDFlink&u tm source=articlePDF&

Convalescent plasma in the management of moderate Anup Agarwal et al. To assess the effectiveness of https://www.bmj.com/c CTRI/2020/04/02 12 October 2020 BMJ COVID‐19 in India: An open‐label parallel‐arm phase II RCT India and PLACID Convalescent plasma Convalescent plasma for the treatment ontent/371/bmj.m3939 4775 multicentre randomized controlled trial (PLACID Trial) Collaborators of COVID‐19

https://www.medrxiv.or To demonstrate the efficacy and safety of Convalescent Plasma used to Convalescent Plasma for COVID‐19: A multicenter, g/content/10.1101/2020 01‐Sep MedRxiv RCT Spain Avendaño‐Solà et al. NCT04345523 Convalescent plasma prevent progression to severe disease randomized clinical trial .08.26.20182444v3.full.p or death in hospitalized patients with df earlier forms of COVID‐19

https://www.medrxiv.or Gargling with 1% Early viral clearance among COVID‐19 patients when povidone‐iodine To assess the ability of regular gargling Nurul Azmawati g/content/10.1101/2020 09‐Sep MedRxiv gargling with Povidone‐Iodine and Essential oils ‐ a RCT Malaysia NCT04410159 (Betadine®), essential to eliminate SARS‐CoV‐2 in the Mohamed et al. .09.07.20180448v1.full.p clinical trial. oils (Listerine®) or tap oropharynx and nasopharynx. df water

https://www.medrxiv.or To investigate whether tocilizumab has Tocilizumab in Hospitalized Patients With COVID‐19 g/content/10.1101/2020 12/09/2020 MedRxiv RCT USA Rosas et al. NCT04320615 Tocilizumab clinical benefit in hospitalized patients Pneumonia .08.27.20183442v2.full.p with severe COVID‐19 pneumonia. df

https://www.sciencedir Efficacy and safety of triazavirin therapy for coronavirus ect.com/science/article/ ChiCTR20000300 To assess the efficacy of Triazavirin 08‐Sep Engineering RCT China Wu et al. Triazavirin disease 2019: A pilot randomized controlled trial pii/S2095809920302411 001 (TZV) for Covid‐19 ?via%3Dihub

To evaluate the efficacy of treatment Patient‐Reported Health Outcomes After Treatment of https://assets.researchs with intravenous and/or nebulized COVID‐19 with Nebulized and/or Intravenous Neutral quare.com/files/rs‐ BMC Infectious neutral electrolyzed neutral electrolyzed saline combined 10‐Sep Electrolyzed Saline Combined with Usual Medical Care RCT Cuba Delgado‐Enciso et al. 68403/v1/e14a5067‐ RPCEC00000309 Diseases. saline with usual medical care versus usual Versus Usual Medical care alone: A Randomized, Open‐ cd36‐4094‐9c29‐ medical care alone, in ambulatory Label, Controlled Trial. 4bb66ac46805.pdf patients with COVID‐19.

https://www.sciencedir Computers in Prediction of respiratory decompensation in Covid‐19 ect.com/science/article/ 01‐Sep‐20 Biology and RCT USA Burdick et al. NCT04390516 NA NA patients using machine learning: The READY trial pii/S0010482520302845 Medicine ?via%3Dihub

Journal of https://onlinelibrary.wil Effectiveness of remdesivir for the treatment of 19‐Aug‐20 Medical Review China Jiang et al. ey.com/doi/abs/10.1002 NA Remdesivir Remdesivir and its clinical effect hospitalized Covid‐19 persons: a network meta‐analysis Virology /jmv.26443

Sofosbuvir and daclatasvir compared with standard of https://academic.oup.co Journal of care in the treatment of patients admitted to hospital m/jac/advance‐ IS sofosbuvir and dalatasvir effective in 19‐Aug‐20 Antimicrobial RCT Iran Sadeghi et al. IRCT2020012804 sofosbuvir/daclatasvir with moderate or severe coronavirus infection (COVID‐ article/doi/10.1093/jac/ COVID patients? Chemotherapy 6294N2 19): a randomized controlled trial dkaa334/5889948

https://stemcellres.biom Are human umbilical cord Stem Cell Treatment of severe COVID‐19 with human umbilical edcentral.com/articles/1 ChiCTR20000314 umbilical cord mesenchymal stem cell infusion 18‐Aug‐20 Research & RCT China Shu et al. cord mesenchymal stem cells 0.1186/s13287‐020‐ 94 mesenchymal stem cells effective and safe for the treatment of Therapy 01875‐5 severe COVID?

Journal of "Effect of Calcifediol Treatment and best Available https://www.sciencedir Evaluate the effect of calcifediol on ICU Steroid Therapy versus best Available Therapy on Intensive Care Marta Entrenas ect.com/science/article/ admission and mortality among October Biochemistry Unit Admission and Mortality Among Patients RCT Spain NCT04366908 Calcifediol Castillo, et al. pii/S0960076020302764 patients hospitalized for COVID‐19 and Molecular Hospitalized for COVID‐19: A Pilot Randomized Clinical Biology study ?via%3Dihub

Effect of an Inactivated Vaccine Against SARS‐CoV‐2 on https://jamanetwork.co To assess the safety and ChiCTR20000318 13 August 2020 JAMA Safety and Immunogenicity Outcomes Interim Analysis Vaccine ‐ Phase I and II China Shengli Xia, et al. m/journals/jama/fullarti Inactivated vaccine immunogenicity of this whole virus 09 of 2 Randomized Clinical Trials cle/2769612 inactivated vaccine

https://jamanetwork.co Effect of Remdesivir vs Standard Care on Clinical Status Christoph D. Spinner, Effect of remdesivir in patients with 21 August 2020 JAMA RCT USA m/journals/jama/fullarti NCT04292730 Remdesivir at 11 Days in Patients With Moderate COVID‐19 et al. moderate COVID19 cle/2769871

Drug treatments for covid‐19: living systematic review International Reed AC Siemieniuk, https://www.bmj.com/c Living systematic review and network 30 July 2020 BMJ Systematic Review NA All treatments and network meta‐analysis Collaboration et al. ontent/370/bmj.m2980 meta‐analysis

https://www.medrxiv.or Vaccine: RNA vaccines To assess the safety and RNA‐Based COVID‐19 Vaccine BNT162b2 Selected for a USA/ g/content/10.1101/2020 28‐Aug MedRXiv RCT Walsh et al. NCT04368728 BNT162b1 and immunogenicity of varying dose levels Pivotal Efficacy Study Germany .08.17.20176651v2.full.p BNT162b2 of vaccines BNT162b1 and BNT162b2. df https://academic.oup.co Clinical Methylprednisolone as Adjunctive Therapy for Patients Assess the efficacy of short‐term Christiane Maria m/cid/advance‐ 12 August 2020 Infectious Hospitalized With COVID‐19 (Metcovid): A Randomised, RCT Brazil NCT04343729 Methylprednisolone methylprednisolone in patients with Prado Jeronimo, et al. article/doi/10.1093/cid/ Diseases Double‐Blind, Phase IIb, Placebo‐Controlled Trial COVID‐19 ciaa1177/5891816

https://academic.oup.co Assess the efficacy and safety of Clinical AVIFAVIR for Treatment of Patients with Moderate Andrey A. m/cid/advance‐ favipiravir in moderate COVID19 and 09 August 2020 Infectious COVID‐19: Interim Results of a Phase II/III Multicenter RCT Russia NCT04434248 Favipiravir Ivashchenko, et al. article/doi/10.1093/cid/ select the optimal dosing regimen for Diseases Randomized Clinical Trial ciaa1176/5890024 further evaluation (Phase III).

International https://www.sciencedir SARS‐CoV‐2 Clearance in COVID‐19 Patients with Efficacy of Novaferon and Novaferon + Journal of ect.com/science/article/ ChiCTR20000294 Preprint Novaferon Treatment: A Randomized, Open‐label, China Fang Zheng, et al. Novaferon Lopinavir/ritonavir in moderate and Infectious pii/S120197122030597X 96 Parallel Group Trial severe COVID19. Diseases ?via%3Dihub

https://www.medrxiv.or Telmisartan for treatment of Covid‐19 patients: an open Mariano Duarte, et Assess the anti‐inflammatory effect of Preprint medRxiv RCT Argentina g/content/10.1101/2020 NCT04355936 Telmisartan randomized clinical trial. Preliminary report. al. telmisartan in COVID‐19 patients .08.04.20167205v2

https://ccforum.biomed Auxora versus standard of care for the treatment of central.com/articles/10. Safety and tolerability of auxora in 14 August 2020 Critical Care severe or critical COVID‐19 pneumonia: results from a RCT USA Joseph Miller, et al. NCT04345614. Auxora 1186/s13054‐020‐03220‐ severe or critical COVID‐19 randomized controlled trial x

Immunogenicity and Safety of a SARS‐CoV‐2 Inactivated https://www.medrxiv.or Vaccine in Healthy Adults Aged 18‐59 years: Report of Is this SARS CoV 2 inactivated vaccine Preprint medRxiv Phase II vaccine RCT China Yanjun Zhang, et al. g/content/10.1101/2020 NCT04352608 Inactiviated Vaccine the Randomized, Double‐blind, and Placebo‐controlled safe and well tolerated? Phase 2 Clinical Trial .07.31.20161216v1

Beneficial effects of colchicine for moderate to severe https://www.medrxiv.or To evaluate the efficacy of colcihcine in Preprint medRxiv COVID‐19: an interim analysis of a randomized, double‐ RCT Brazil Maria IF Lopes, et al. g/content/10.1101/2020 RBR‐8jyhxh Colchicine treating severe and moderate COVID‐ blinded, placebo controlled clinical trial .08.06.20169573v2 19

https://www.nejm.org/ NVX‐CoV2373; Assess the safety and tolerability of the 2 September Phase 1–2 Trial of a SARS‐CoV‐2 Recombinant Spike NEJM Phase I vaccine RCT Australia Cheryl Keech, et al. doi/full/10.1056/NEJMo NCT04368988 recombinant NVX‐COV2373 recombinant vaccine in 2020 Protein Nanoparticle Vaccine a2026920 nanoparticle vaccine healthy subjects.

Asses the efficacy of https://www.nejm.org/ Hydroxychloroquine with or without Azithromycin in Alexandre B. hydroxychloroquine with and without 23 July 2020 NEMJ RCT Brazil doi/10.1056/NEJMoa201 NCT04322123 Hydroxychloroquine Mild‐to‐Moderate Covid‐19 Cavalcanti, et al. azithromycin in mild to moderate 9014 COVID19

Hydroxychloroquine, Tocilizumab, Journal of Viveksandeep https://onlinelibrary.wil Systematic Review and Meta‐analysis of Effectiveness of Remdesivir, Asses overall efficacy of treatments 6 July 2020 Medical Systematic review USA Thoguluva ey.com/doi/epdf/10.100 NA Treatment Options Against SARS‐CoV‐2 infection convalescent plasma, that have been studied thus far. Virology Chandrasekar, et al. 2/jmv.26302 steroids, lopinavir/ritonavir

https://www.medrxiv.or Is itolizumab a safe and efficient Use of a humanized anti‐CD6 monoclonal antibody Preprint medRxiv CT Cuba Yayquier Díaz, et al. g/content/10.1101/2020 RPCEC00000311 Itolizumab treatment for COVID 19 in elderley (itolizumab) in elderly patients with moderate COVID‐19 .07.24.20153833v1 patients?

https://www.medrxiv.or Efficacy and tolerability of bevacizumab in patients with Is bevacizumab a safe and efficient Preprint medRxiv CT China, Italy Jiaojiao Pang, et al g/content/10.1101/2020 NCT04275414 Bevacizumab severe Covid ‐19 treatment for severe COVID 19? .07.26.20159756v1

A clinical pilot study on the safety and efficacy of aerosol https://www.sciencedir To evaluate the efficacy and safety of EClinicalMedici ChiCTR20000302 IFN‐κ plus trefoil factor 29 July 2020 inhalation treatment of IFN‐κ plus TFF2 in patients with CT China + USA Weihui et al. ect.com/science/article/ intranasal inhalation of TFF2 and IFN‐κ ne (Lancet) 62 2 moderate COVID‐19 pii/S2589537020302224 protein for SARS‐CoV‐2 infection

A Small‐Scale Medication of Leflunomide as a Treatment https://link.springer.co Virologica ChiCTR Is leflunomide effective in COVID‐19 21 July 2020 of COVID‐19 in an Open‐Label Blank‐Controlled Clinical CT China Hu et al. m/article/10.1007%2Fs1 leflunomide Sinica 2000030058 patients? Trial 2250‐020‐00258‐7

https://www.thelancet.c Folegatti et al. on To assess the immunogenicity, Safety and immunogenicity of the ChAdOx1 nCoV‐19 om/journals/lancet/artic ISRCTN behalf of the Oxford ChAdOx1 nCoV‐19 reactogenicity, and safety of 20‐Jul Lancet vaccine against SARS‐CoV‐2: a preliminary report of a RCT UK le/PIIS0140‐ 15281137; COVID Vaccine Trial vaccine vaccination with ChAdOx1 nCoV‐19 in phase 1/2, single‐blind, randomised controlled trial NCT04324606 Group 6736(20)31604‐ single‐dose and two‐dose regimens. 4/fulltext

Immunogenicity and safety of a recombinant adenovirus https://www.thelancet.c Phase 2 trial to further evaluate the adenovirus type‐5 (Ad5)‐ type‐5‐vectored COVID‐19 vaccine in healthy adults aged om/action/showPdf?pii= immunogenicity and safety in a larger 20‐Jul Lancet RCT China Feng‐Cai Zhu et al. NCT04341389 vectored COVID‐19 18 years or older: a randomised, double‐blind, placebo‐ S0140‐ population, and to determine an vaccine controlled, phase 2 trial 6736%2820%2931605‐6 appropriate dose for the efficacy study

To assess safety, tolerability, and https://www.nature.co Phase 1/2 study of COVID‐19 RNA vaccine BNT162b1 in immunogenicity of RNA Vaccine 12 August 2020 Nature Phase 1/2 trial USA/Germany Mulligan et al. m/articles/s41586‐020‐ NCT04368728 RNA Vaccine BNT162b1 adults candidate in a dose escalation study 2639‐4 among healthy adults.

https://www.medrxiv.or To complement previous reported data NCT04380701, by providing a detailed characterisation Concurrent human antibody and TH1 type T‐cell Germany/ g/content/10.1101/2020 20‐Jul‐20 Medrxiv Phase 1/2 trial Sahin et al. EudraCT: 2020‐ RNA Vaccine BNT162b1 of antibody and T76 cell immune responses elicited by a COVID‐19 RNA vaccine USA .07.17.20140533v1.full.p 001038‐36 responses elicited by BNT162b1 df vaccination.

https://www.nejm.org/ An mRNA Vaccine against SARS‐CoV‐2 — Preliminary To evaluate the safety and 14‐Jul NEMJ Phase 1 trial USA Jackson et al. doi/pdf/10.1056/NEJMo NCT04283461 mRNA‐1273 vaccine Report immunogenicity of mRNA‐1273 vaccine a2022483

Effect of Hydroxychloroquine in Hospitalized Patients Horby et al. https://www.nejm.org/ ISRCTN To assess the safety and efficacy of 08‐Oct NEJM with COVID‐19: Preliminary results from a multi‐centre, RCT UK (RECOVERY doi/10.1056/NEJMoa202 50189673, Hydroxychloroquine hydroxychloroquine in patients randomized, controlled trial. Collaborative Group) 2926 NCT04381936 hospitalized with COVID‐19

A Multicenter, randomized, open‐label, controlled trial https://www.medrxiv.or to evaluate the efficacy and tolerability of To evaluate HCQ efficacy and RCT & retrospective g/content/10.1101/2020 10‐Jul Medrxiv hydroxychloroquine and a retrospective study in adult Taiwan Cheng‐Pin Chen et al. NCT04384380 Hydroxychloroquine tolerability in adult patients with mild cohort study .07.08.20148841v1.full.p patients with mild to moderate Coronavirus disease to moderate COVID‐19. 2019 (COVID‐19) df Annals of https://www.acpjournal To investigate whether Hydroxychloroquine in Nonhospitalized Adults With 16‐Jul Internal RCT USA Skipper et al. s.org/doi/10.7326/M20‐ NCT04308668 Hydroxychloroquine hydroxychloroquine could reduce Early COVID‐19 ‐ A Randomized Trial Medicine 4207 COVID‐19 severity in adult outpatients

Is early treatment with Hydroxychloroquine Alone or in Combination with https://papers.ssrn.com hydroxychloroquine (HCQ) with our Hydroxychloroquine, Preprint Lancet Cobicistat‐Boosted Darunavir for Treatment of Mild RTC Spain Mitjà et al, /sol3/papers.cfm?abstra NCT04304053 without cobicistat/darunavir more Darunavir, Cobicistat COVID‐19: A Cluster‐Randomized Clinical Trial ct_id=3615997 efficacious than no‐treatment for outpatients with mild Covid‐19?

https://assets.researchs To assess the effcacy and safety of A pragmatic randomized controlled trial reports the quare.com/files/rs‐ hydroxychloroquine therapy on SARS‐ ResearchSquar Magnus Nakrem Preprint efficacy of hydroxychloroquine on coronavirus disease RCT Norway 44055/v1/3fb11155‐ NCT04316377 Hydroxychloroquine CoV‐2 oropharyngeal viral kinetics in e Lyngbakken, et al. 2019 viral kinetics d83c‐48a0‐ae74‐ patients hospitalized with moderately b3cce9a5eac3.pdf severe COVID‐19.

Open Forum Evaluate the antiviral activity and Antiviral Activity and Safety of Darunavir/Cobicistat for https://pubmed.ncbi.nl 11 June 2020 Infectious RCT China Jun Chen, et al. NCT04252274 Darunavir, Cobicistat safety of darunavir/cobicistat (DRV/c) the Treatment of COVID‐19 m.nih.gov/32671131/ Diseases for treating mild COVID‐19

lopinavir/ritonavir; SN arbidol; https://link.springer.co To assess the current evidence Comprehensive Systematic and Statistical Review of Coronavirus Disease Systematic review & Juan A. Siordia Jr et hydroxychloroquine; 15‐Jul‐20 USA m/article/10.1007%2Fs4 N/A regarding human controlled COVID‐19 Clinical 19 Treatment Trials Meta‐analysis al. remdesivir; tocilizumab; 2399‐020‐00399‐6 treatment trials. Medicine favipiravir; heparin; dexamethasone https://www.researchga Compared outcomes of Ivermectin‐ Abu Taiub te.net/profile/Abu_Taiu Doxycycline vs. Hydroxychloroquine‐ A Randomized Trial of Ivermectin‐Doxycycline and Ivermectin, Doxycycline, BMC Infectious Mohammed b_Mohammed_Mohiud Azithromycin combination therapy Preprint Hydroxychloroquine‐Azithromycin therapy on COVID19 RT Bangladesh NCT04434144 Hydroxychloroquine, Diseases Mohiuddin din_Chowdhury2/public COVID19 patients with mild to patients. Azithromycin Chowdhury, et al. ation/342159343_A_co moderate disease. mparative observationa

https://www.cochraneli Assess the effectiveness of Convalescent plasma, updated Convalescent plasma or hyperimmune immunoglobulin International brary.com/cdsr/doi/10.1 convalescent plasma and Cochrane Systematic review Piechotta V, et al. NA hyperimmune 12/10/20 for people with COVID‐19: a living systematic review Collaboration 002/14651858.CD01360 hyperimmune immunoglobulin for immunoglobulin 0.pub2/abstract treating people with COVID19

A Randomized, Open‐label, Controlled Clinical Trial of https://onlinelibrary.wil Advanced ChiCTR20000298 Efficacy of azvudine in treating mild Preprint Azvudine Tablets in the Treatment of Mild and RCT China Zhigang Ren, et al. ey.com/doi/epdf/10.100 Azvudine Science 53 COVID19 patients Common COVID‐19, A Pilot Study 2/advs.202001435

To evaluate the effect of treatment JAMA Network Effect of Colchicine vs Standard Care on Cardiac and https://jamanetwork.co with colchicine on cardiac and Open: Inflammatory Biomarkers and Clinical Outcomes in Randomized clinical m/journals/jamanetwor 24/06/2020 Greece Deftereos et al. NCT04326790 Colchicine inflammatory biomarkers and clinical Infectious Patients Hospitalized With Coronavirus Disease 2019The trial kopen/fullarticle/276759 outcomes in patients hospitalized with Diseases GRECCO‐19 Randomized Clinical Trial 3 COVID‐19.

The International Febuxostat Therapy in Outpatients With Suspected https://pubmed.ncbi.nl IRCT2019072704 Hydroxychloroquine, Is febuxostat effective in comparision 30‐Jun‐20 RCT Iran Davoodi et al. Journal of COVID‐19: A Clinical Trial m.nih.gov/32603531/ 434N1 febuxostat with hydroxychloroquine? Clinical Practice

https://www.nejm.org/ doi/pdf/10.1056/NEJMo Horby et al. ISRCTN To test the effectiveness of Effect of Dexamethasone in Hospitalized Patients with a2021436?casa_token= 17 July 2020 NEMJ RCT UK (RECOVERY Writing 50189673, Dexamethasone dexamethasone in patients hospitalized COVID‐19: Preliminary Report H8GAcaEgprUAAAAA:m Committee) NCT04381936 with COVID‐19 _9Qlb5FCP6d6YPLPMryK LqVP0QTUouiQsD39ki 1 To determine whether a 6‐day course https://www.medrxiv.or of intravenous methylprednisolone GLUCOCOVID: A controlled trial of methylprednisolone g/content/10.1101/2020 EudraCT number: (MP) improves outcome in patients 18‐Jun medRxiv RCT Spain Corral‐Gudino et al. methylprednisolone in adults hospitalized with COVID‐19 pneumonia .06.17.20133579v1.full.p 2020‐001934‐37 with SARS CoV‐2 infection at risk of df developing Acute Respiratory Distress Syndrome (ARDS)

https://immunology.scie Science Inhibition of Bruton tyrosine kinase in patients with Is acalabrutinib effective in severe 05‐Jun‐20 RCT USA Roschewski et al. ncemag.org/content/5/4 NA Acalabrutinib Immunology severe COVID‐19 COVID‐19 patients? 8/eabd0110

Were the non‐pharmaceutical 8 June 2020 ‐ https://www.nature.co Estimating the effects of non‐pharmaceutical Non‐pharmaceutical interventions implemented in Accelerated Nature Modelling UK Seth Flaxman, et al. m/articles/s41586‐020‐ NA interventions on COVID‐19 in Europe interventions European countries effective in limiting publication 2405‐7 the spread of SARS CoV‐2?

https://www.nature.co Nature ‐ The Janus kinase 1/2 inhibitor ruxolitinib in COVID‐19 Efficacy and safety of ruxolitinib in 8 May 2020 Retrospective analysis Germany F. La Rosée, et al. m/articles/s41375‐020‐ Ruxolitinib Leukemia with severe systemic hyperinflammation severe COVID19 0891‐0

https://www.sciencedir Lancet Claudio Ucciferri, et ect.com/science/article/ Is canakinumab a safe and effective 8 June 2020 Reheumatolog Canakinumab in a subgroup of patients with COVID‐19 Retrospective analysis Italy NA Canakinumab al. pii/S2665991320301673 treatment against COVID19? y ?via%3Dihub

Use of personal protective equipment against To examine the protective effects of https://www.bmj.com/c 10‐Jun‐20 BMJ coronavirus disease 2019 by healthcare professionals in Observational study China Min Liu et al. NA NA appropriate personal protective ontent/369/bmj.m2195 Wuhan, China: cross sectional study equipment

https://www.thelancet.c Effects of non‐pharmaceutical interventions on COVID‐ om/journals/lanpub/arti What is the impact of different control The Lancet 02‐Jun‐20 19 cases, deaths, and demand for hospital services in the Modelling study UK Gavines et al. cle/PIIS2468‐ NA NA measures for mitigating the burden of Digital Healt UK: a modelling study 2667(20)30133‐ COVID‐19 X/fulltext#%20

Clinical performance of the Luminex NxTAG CoV Journal of https://jcm.asm.org/con Extended Panel for SARS‐CoV‐2 detection in Jonathan Hon‐Kwan Evaluation of Luminex NxTAG in COVID‐ 01‐Jun‐20 Clinical Diagnostic Hong‐Kong tent/early/2020/05/29/J NA Nucleic acid test nasopharyngeal specimens of COVID‐19 patients in Hong Chen 19 detection Microbiology Kong CM.00936‐20

https://www.sciencedir Clinical Clinical evidence for repurposing chloroquine and Systematic review / Australia/Sri ect.com/science/article/ Hydroxychloroquine, Does hydroxychloroquine have 26‐May‐20 Microbiology hydroxychloroquine as antiviral agents: a systematic Rodrigo et al. NA Meta‐analysis Lanka pii/S1198743X20302937 chloroquine antiviral effect? and Infection review ?via%3Dihub

https://www.medrxiv.or To test the performance characteristics Kinetics of the humoral immune response to SARS‐CoV‐ g/content/10.1101/2020 of seven commercially available 14‐Jun MedRxiv 2: comparative analytical performance of seven Diagnostic Belgium Herroelen et al. N/A Antibody test .06.09.20124719v2.full.p serology tests for detection of commercial serology tests df antibodies against the SARS‐CoV‐2 https://www.medrxiv.or To assess the therapeutic efficacy of Therapeutic effectiveness of interferon‐alpha 2b against g/content/10.1101/2020 09‐Jun MedRxiv observational study Cuba Pereda et al. RPCEC00000318 Interferon alpha 2b IFN‐α2b in patients infected with SARS‐ COVID‐19: the Cuban experience .05.29.20109199v1.full.p CoV‐2 df

https://www.medrxiv.or ICON (Ivermectin in COvid Nineteen) study: Use of To determine whether Ivermectin is Cepelowicz Rajter et g/content/10.1101/2020 10‐Jun MedRxiv Ivermectin is Associated with Lower Mortality in Retrospective analysis USA N/A Ivermectin associated with lower mortality rate in al. .06.06.20124461v2.full.p Hospitalized Patients with COVID19 patients hospitalized with COVID‐19 df

To assess the efficacy of lenzilumab https://www.medrxiv.or therapy in patients hospitalized with prospective study with First Clinical Use of Lenzilumab to Neutralize GM‐CSF in g/content/10.1101/2020 severe COVID‐19 pneumonia, who had 14‐Jun MedRxiv FDA emergency use USA Temesgen et al. N/A Lenzilumab Patients with Severe and Critical COVID‐19 Pneumonia .06.08.20125369v2.full.p clinical and/or biomarker evidence for IND df increased risk of progression to respiratory failure. To investigate whether soluble https://www.medrxiv.or urokinase plasminogen activator Low levels of the prognostic biomarker suPAR are prospective cohort g/content/10.1101/2020 receptor (suPAR) can aid in identifying 02‐Jun MedRxiv predictive of mild outcome in patients with symptoms of Denmark/USA Eugen‐Olsen et al. N/A Prognostic biomarker study .05.27.20114678v1.full.p patients with low risk of respiratory COVID‐19 ‐ a prospective cohort study df failure when presenting with symptoms of COVID‐19.

https://www.medrxiv.or To determine if Low Dose‐Radiation Low‐Dose Whole‐Lung Radiation for COVID‐19 g/content/10.1101/2020 Therapy can reduce pulmonary 08/06/2020 MedRxiv Pneumonia: Planned Day‐7 Interim Analysis of a CT USA Hess et al. NCT: 04366791 Low dose radiation .06.03.20116988v1.full.p inflammation associated with COVID‐ Registered Clinical Trial df 19 pneumonia.

https://www.medrxiv.or To evaluate the safety and efficacy of Efficacy and Safety of Leflunomide for Refractory COVID‐ g/content/10.1101/2020 ChiCTR20000300 02‐Jun MedRxiv CT China Wang et al. Leflunomide leflunomide for the treatment of 19: An Open‐label Controlled Study .05.29.20114223v1.full.p 58 refractory COVID‐19 in adult patients. df

https://www.medrxiv.or To explore the effect of high fiber whey Nano short peptide nutrition intervention on the g/content/10.1101/2020 08‐Jun MedRxiv Retrospective analysis China Zhang et al. N/A enteral nutrition short peptide enteral nutrition on the prognosis of patients with COVID‐19 .06.03.20083980v1.full.p prognosis of patients with COVID‐19 df

https://www.medrxiv.or To determine if ozonated autohemotherapy is associated with a Ozone therapy for patients with SARS‐COV‐2 prospective cohort Spain/ g/content/10.1101/2020 05‐Jun MedRxiv Hernández et al. N/A Ozone therapy shorter time to clinical improvement in pneumonia: a single‐center prospective cohort study study USA/Canada .06.03.20117994v1.full.p patients with severe COVID‐19 df pneumonia.

https://www.medrxiv.or To determine the effect of Center for CIGB‐258 immunomodulatory peptide: a novel Venegas‐Rodriguez et g/content/10.1101/2020 CIGB‐258 immuno‐ Genetic Engineering and Biotechnology 02‐Jun MedRxiv promising treatment for critical and severe COVID‐19 CT Cuba RPCEC00000313 al. .05.27.20110601v1.full.p modulatory peptide (CIGB)‐258 therapy in seriously, or patients df critically ill patients with COVID‐19.

To determine the clinical outcomes of A cohort study to evaluate the effect of combination https://www.medrxiv.or older COVID‐19 patients who received Vitamin D, Magnesium and Vitamin B12 (DMB) on g/content/10.1101/2020 Vitamin D, Magnesium 02‐Jun MedRxiv Observational study Singapore Chuen Wen Tan et al. N/A Vitamin D, Magnesium and Vitamin progression to severe outcome in older COVID‐19 .06.01.20112334v1.full.p and Vitamin B12 (DMB) B12 (DMB) compared to those who did patients. df not

https://www.medrxiv.or To evaluate differences in morbidity Therapeutic Anticoagulation Is Associated with and mortality among mechanically g/content/10.1101/2020 03‐Jun MedRxiv Decreased Mortality in Mechanically Ventilated COVID‐ Retrospective analysis USA Trinh et al. N/A anticoagulation agents ventilated patients with COVID‐19 .05.30.20117929v1.full.p 19 Patients treated with therapeutic versus df prophylactic anticoagulation

https://translational‐ EudraCT (2020‐ Tocilizumab for patients with COVID‐19 pneumonia. The medicine.biomedcentral 001110‐38); To evaluate efficacy of tocilizumab in 21 October 2020of Translational M CT Italy Perrone et al. Tocilizumab TOCIVID‐19 phase 2 trial .com/articles/10.1186/s clinicaltrials.gov COVID‐19 pneumonia patients. 12967‐020‐02573‐9 (NCT04317092)

To compare SAMBA II SARS‐CoV‐2 https://www.medrxiv.or performance against the standard lab Rapid point of care nucleic acid testing for SARS‐CoV‐2 in prospective clinical UK/South g/content/10.1101/2020 RTPCR test in suspected COVID‐19 02/06/2020 MedRxiv hospitalised patients: a clinical trial and implementation trial and observational Dami Collier, et al. NCT04326387 Nucleic acid diagnostic Africa .05.31.20114520v1.full.p cases presenting to hospital, followed study study df by a hospital‐based implementation study. To compare three fully automated https://www.medrxiv.or large‐scale laboratory analyzer test Side by side comparison of three fully automated SARS‐ Diagnostic g/content/10.1101/2020 systems, with particular emphasis on 06‐Jun MedRxiv Austria Perkmann et al. N/A Antibody diagnostic CoV‐2 antibody assays with a focus on specificity comparison .06.04.20117911v2.full.p specificity, which is crucial for an df adequate positive predictive value given the current low seroprevalence

https://www.medrxiv.or To describe initial experience using a Implementation and evaluation of a novel real‐time commercially‐available multiplex two‐ Diagnostic validation g/content/10.1101/2020 05‐Jun MedRxiv multiplex assay for SARS‐CoV‐2: In‐field learnings from a Australia Williams et al. N/A Nucleic acid diagnostic step nested tandem RT‐PCR assay for study .06.03.20117267v1.full.p clinical microbiology laboratory the detection of coronaviruses that df infect humans, including SARS‐CoV‐2

https://www.medrxiv.or Diagnostic for To construct and validate a cell‐free Detection of SARS‐CoV‐2 neutralizing antibodies with a Diagnostic validation USA/Switzerla g/content/10.1101/2020 indentifying suitable assay to measure neutralizing 02‐Jun MedRxiv Danh et al. N/A cell‐free PCR assay study nd .05.28.20105692v1.full.p Convalescent plasma antibodies in order to identify suitable df donors donors of convalescent plasma

https://www.medrxiv.or To evaluate the real‐world diagnostic Diagnostic accuracy of a host response point‐of‐care test diagnostic clinical g/content/10.1101/2020 accuracy of FebriDx for the 02‐Jun MedRxiv UK Clark et al. ISRCTN14966673 Diagnostic for identifying COVID‐19 evaluation .05.27.20114512v1.full.p identification of COVID‐19 in df hospitalised adults

https://www.sciencedir Journal of Alltest rapid lateral flow immunoassays is reliable in To analyze the diagnostic performance ect.com/science/article/ August 2020 Clinical diagnosing SARS‐CoV‐2 infection from 14 days after Diagnostic assay Spain García et al. NA NA of one serologic rapid test in COVID‐19 pii/S1386653220302158 Virology symptom onset: A prospective single‐center study patients ?via%3Dihub

Poor‐sleep is associated with slow recovery from Effects of sleep quality on recovery Brain, https://www.sciencedir lymphopenia and an increased need for ICU care in from lymphopenia and clinical 06‐Jun‐20 Behaviour and Retrospective study China Zhang et al. ect.com/science/article/ NA NA hospitalized patients with COVID‐19: A retrospective outcomes in hospitalized patients with Imunity cohort study pii/S0889159120309946 COVID‐19

To assess the overall benefit–risk of the Remdesivir in Treatment of COVID-19: A Systematic https://doi.org/10.1007/ use of remdesivir as a treatment for 28 May 2020 Drug Safety Systematic review UK Miranda Davies, et al. NA Remdesivir Benefit–Risk Assessment s40264‐020‐00952‐1 COVID‐19 compared with standard of care, placebo or other treatments

To determine the frequency of venous Routine Venous Thromboembolism Prophylaxis May Be DOI: Venous Society of Thomas K. Maatman, thromboembolism (VT) in critically ill 27 May 2020 Inadequate in the Hypercoagulable State of Severe Observational study USA 10.1097/CCM.00000000 NA thromboembolism Critical Care et al. COVID19 patients who recieved Coronavirus Disease 2019 prophylaxis 00004466 prophylaxis for VT. Effect of Convalescent Plasma Therapy on Time to Is convalescent plasma a safe and doi:10.1001/jama.2020. ChiCTR20000297 3 June 2020 JAMA Clinical Improvement in Patients With Severe and Life‐ RCT China Ling Li, et al. Convalescent Plasma efficient treatment for severe 10044 57 threatening COVID‐19 ‐ A Randomized Clinical Trial COVID19?

Journal of the https://www.sciencedir American Ignacio J. Amat‐ ect.com/science/article/ NCT03201185 To analyze if ramipril modifies the risk Preprint Ramipril in High Risk Patients with COVID‐19 Retrospective analysis Spain Ramipril College of Santos, et al. pii/S073510972035395X (source RCT) for COVID‐19. Cardiology ?via%3Dihub

Should health care workeers wear https://journals.plos.org surgical masks or N95 respirators The need of health policy perspective to protect Systematic review / Primiano Iannone, et /plosone/article?id=10.1 during the routine care (not 3 June 2020 PlosOne Healthcare Workers during COVID‐19 pandemic. A Italy NA N95 respirators Meta‐analysis al. 371/journal.pone.02340 involving aerosol generating GRADE rapid review on the N95 respirators effectiveness 25 procedures) of COVID‐19 suspected or affected patients? Investigate the effects of physical Physical distancing, face masks, and eye protection to PROSPERO: distance, face masks, and eye International https://doi.org/10.1016/ 1 June 2020 Lancet prevent person‐to‐person transmission of SARS‐CoV‐2 Systematic review Derek K Chu, et al. CRD4202017704 PPE protection on virus transmission in collaboration S0140‐6736(20)31183‐1 and COVID‐19: a systematic review and meta‐analysis 7 health‐care and non‐health‐care (eg, community) settings

Diabetes, Exposure to DPP‐4 inhibitors and COVID‐19 among Gian Paolo Fadini, et https://pubmed.ncbi.nl Do DPP‐4 inhinbitors have a protective Preprint obesity & people with type 2 Case population study Italy NA DPP‐4 inhibitors al. m.nih.gov/32463179/ effect agains COVID19? metabolism diabetes. A case‐control study

https://www.nejm.org/ A Randomized Trial of Hydroxychloroquine as Is hydroxychloroquine effective in post‐ 03 June 2020 NEJM RCT USA / Canada D.R. Boulware, et al. doi/full/10.1056/NEJMo NCT04308668. Hydroxychloroquine Postexposure Prophylaxis for Covid‐19 exposure prohylaxis therapy? a2016638

Can CRISPR technology simplify RT‐PCR Biosensors and Ultra‐sensitive and high‐throughput CRISPR‐Powered https://doi.org/10.1016/ Preprint Diagnostic assay USA Zhen Huang, et al. NA CRISPR RT‐PCR for SARS CoV2 and be effective for Bioelectronics COVID‐19 diagnosis j.bios.2020.112316 diagnos?

https://www.gastrojour Famotidine Use is Associated with Improved Clinical Do COVID19 patients taking famotidine Gastroenterolo Daniel E. Freedberg, nal.org/article/S0016‐ Preprint Outcomes in Hospitalized COVID‐19 Patients: A Retrospective study USA NA Famotidine have a lower risk of intubation and/or gy et al. 5085(20)34706‐ Propensity Score Matched Retrospective Cohort Study death? 5/fulltext

International https://www.nejm.org/ Is a 5 day course of remedesivir as Remdesivir for 5 or 10 Days in Patients with Severe Covid collaboration/ Jason D. Goldman, et 27 May 2020 NEJM RCT doi/full/10.1056/NEJMo NCT04292899 Remdesivir effective as a 10 course in treating 19 Gilead al. moderately ill COVID19 patients? Sciences a2015301

https://www.nejm.org/ Is remdesivir an effective treatment for Remdesivir for the Treatment of Covid‐19 — Preliminary International 22 May 2020 NEJM RCT J.H. Beigel, et al. doi/full/10.1056/NEJMo NCT04280705 Remdesivir reducing time to recovery in COVID19 Report collaboration a2007764 patients?

Journal of Ruxolitinib in treatment of severe coronavirus disease To evaluate the efficacy and safety of Allergy and https://doi.org/10.1016/ ChiCTR‐OPN‐ Preprint 2019 (COVID‐19): A multicenter, single‐blind, RCT China Yang Cao, et al. Ruxolitinib ruxolitinib for patients with severe Clinical j.jaci.2020.05.019 2000029580. randomized controlled trial COVID19. Immunology

Clinical Thymosin alpha 1 (Tα1) reduces the mortality of severe https://pubmed.ncbi.nl Is thymosin alpha a safe and effective Preprint Infectious COVID 19 by restoration of lymphocytopenia and Retrospective study China Yueping Liu, et al. NA Thymosin alpha m.nih.gov/32442287/ treatment for severe COVID19? Diseases reversion of exhausted T cells

International https://www.sciencedir Level of protection confered by masks Journal of HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL C Raina MacIntyre, et Preprint Review Australia ect.com/science/article/ NA PPE and respirators for common Infectious TRIALS OF MASKS AND RESPIRATORS al. coronavirus. Diseases pii/S1201971220303994

https://www.thelancet.c om/journals/lanrhe/arti Use of anakinra in patients who were The Lancet 29‐May‐20 Anakinra for severe forms of COVID‐19: a cohort study Cohort study France Huet et al. cle/PIIS2665‐ NA Anakinra admitted to hospital for severe forms Rheumatology 9913(20)30164‐ of COVID‐19 8/fulltext https://www.thelancet.c Safety, tolerability, and immunogenicity of a om/journals/lancet/artic Are different doses of Ad5 vectored recombinant adenovirus type‐5 vectored COVID‐19 Ad5 vectored COVID‐19 22‐May‐20 The Lancet CT China Feng‐Cai Zhu et al. le/PIIS0140‐ NCT04313127 COVID‐19 vaccine safe and vaccine: a dose‐escalation, open‐label, non‐randomised, vaccine immunogenic? first‐in‐human trial 6736(20)31208‐ 3/fulltext

A comparative study on the time to achieve negative https://www.researchsq nucleic acid testing and hospital stays between Danopevir and Antiviral effect of danopevir or 29‐May‐20 Preprint Comparative study China Zhicheng Zhang et al. uare.com/article/rs‐ NA Danoprevir and Lopinavir/Ritonavir in the treatment of lopinavir/ritonavir lopinavir/ritonavir in COVID‐19 patients patients with COVID‐19 28376/v1.pdf

Current Potential of Arbidol for Post‐exposure Prophylaxis of https://link.springer.co Is Arbidol effective in profylaxis of 01‐Jun‐20 Medical COVID‐19 Transmission–A Preliminary Report of a Observational study China Zhang et al. m/content/pdf/10.1007/ NA Arbidol COVID? Science Retrospective Cohort Study s11596‐020‐2203‐3.pdf

Advanced http://ajem.tums.ac.ir/i Journal of Interferon beta‐1a as a Candidate for COVID‐19 IRCT2015091402 Is interferon beta1a effective in 26‐May‐20 CT Iran Payandemehr et al. ndex.php/ajem/article/v Interferon beta1a Emergency Treatment; An Open‐label Single‐Arm Clinical Trial 4017N1 treatment of COVID‐19? Medicine iew/454/307

https://aac.asm.org/con Efficacy and safety of interferon beta‐1a in treatment of Davoudi‐Monfared et IRCT2010022800 To evaluate efficacy and safety of IFN β‐ 13 July 2020 Antiviral Agents RCT Iran tent/early/2020/07/08/ Interferon beta‐1a severe COVID‐19: A randomized clinical trial al. 3449N28 1a in patients with severe COVID‐19. AAC.01061‐20

https://www.medrxiv.or To develop and clinically evaluate an at‐ A serological assay to detect SARS‐CoV‐2 antibodies in at Clinical Evaluation of g/content/10.1101/2020 IRB protocol 30/05/2020 medRxiv USA Karp et al. Antibody diagnostic test home finger‐prick dried blood spot test home collected fingerprick dried blood spots diagnostic test .05.29.20116004v2.full.p #20180015 to detect SARS‐CoV‐2 antibodies df

https://www.medrxiv.or To assess the analytical and clinical Performance evaluation of the point‐of‐care SAMBA II Clinical Evaluation of UK/USA/Sout g/content/10.1101/2020 Nucleic acid diagnostic performance of the SAMBA II 83 SARS‐ 27/05/2020 medRxiv Assennato et al. N/A SARS‐CoV‐2 Test for detection of SARS‐CoV‐2 diagnostic test h Africa .05.24.20100990v2.articl test CoV‐2 Test using panels and clinical e‐info samples. https://www.medrxiv.or To develop and clincally evaluate a new EasyCOV : LAMP based rapid detection of SARS‐CoV‐2 in Clinical Evaluation of g/content/10.1101/2020 saliva RT‐LAMP 30/05/2020 medRxiv France L’Helgouach et al. N/A simple saliva SARS‐CoV‐2 detection test saliva diagnostic test .05.30.20117291v1.full.p diagnostic test based on RT‐LAMP technology df

https://www.medrxiv.or To evaluate the performance of two Evaluation of performance of two SARS‐CoV‐2 Rapid Clinical Evaluation of g/content/10.1101/2020 Antibody rapid COVID 19 IgM/IgG Rapid Diagnostic 27/05/2020 medRxiv whole‐blood finger‐stick IgM‐IgG Combined Antibody France Prazuck et al. N/A diagnostic test .05.27.20112888v1.full.p diagnostic test Tests compared to the gold standard, Tests df RT‐PCR.

https://www.medrxiv.or To show the potential efficacy and Mortality reduction in 46 severe Covid‐19 patients safety of hyperimmune plasma proof of concept g/content/10.1101/2020 29/05/2020 medRxiv treated with hyperimmune plasma. A proof of concept Italy Perotti et al. NCT 04321421 convalescent plasma infusions, obtained from convalescent study .05.26.20113373v1.full.p single arm multicenter interventional trial donors, in COVID‐19 patients with df respiratory failure

https://www.medrxiv.or To analyse the outcomes of COVID‐19 Use of High Flow Nasal Therapy to Treat Moderate to g/content/10.1101/2020 High Flow Nasal patients with moderate‐to‐severe 26/05/2020 medRxiv Retrospective analysis USA Patel et al. Severe Hypoxemic Respiratory Failure in COVID‐19 .05.22.20109355v1.full.p Therapy hypoxemic respiratory failure receiving df High Flow Nasal Therapy

https://www.thelancet.c Hydroxychloroquine or chloroquine with or without a om/journals/lancet/artic USA/Switzerla Are these treatment regimens 22‐May‐20 The Lancet with or without a macrolide for treatment of COVID‐19: Observational study Mehra et al. le/PIIS0140‐ NA Hydroxychloroquine nd associated with in‐hospital death? a multinational registry analysis 6736(20)31180‐ 6/fulltext

https://www.frontiersin. Is Interferon‐a2b efficient in Frontiers in 15 May 2020 Interferon‐a2b Treatment for COVID‐19 CT Canada, China Qiong Zhou, et al. org/articles/10.3389/fim NA Interferon‐a2b accelerating viral clearance and Immunology mu.2020.01061/full reducing inflammation markers?

https://www.medrxiv.or Clinical To examine the role of early Early Short Course Corticosteroids in Hospitalized g/content/10.1101/2020 19 May 2020 Infectious Retrospective study USA Fadel et al. NCT04374071 corticosteroids corticosteroid therapy in patients with Patients with COVID‐19 .05.04.20074609v1.full.p Diseases moderate to severe COVID‐19. df

https://www.medrxiv.or Convalescent plasma treatment of severe COVID‐19: A Is convalescent plasma an effective Preprint medRxiv CT USA Sean T. H. Liu, et al. g/content/10.1101/2020 NA Convalescent plasma matched control study treatment for severe COVID19? .05.20.20102236v1

https://www.thelancet.c Use of renin–angiotensin–aldosterone system inhibitors om/journals/lancet/artic renin–angiotensin–aldos Francisco J de Abajo, Does use of RAAS predispose patients 14 May 2020 Lancet and risk of COVID‐19 requiring admission to hospital: a Case population study Spain le/PIIS0140‐ EUPAS34437 terone system et al. to severe COVID19? case‐population study 6736(20)31030‐ inhibitors, RAAS 8/fulltext To evaluate various methods of chest compressions in patients with Resuscitation of the patient with suspected/confirmed https://journals.viamedi Cardiology Randomized suspected/confirmed SARS‐CoV‐2 Preprint COVID‐19 when wearing personal protective equipment: Poland Marek Malysz, et al. ca.pl/cardiology_journal NA PPE Journal crossover trial infection conducted by medical A randomized multicenter crossover simulation trial /article/view/68336 students wearing full personal protective equipment (PPE) for aerosol

Stefano Bonovas, https://www.nejm.org/ Compassionate Use of Remdesivir in Covid‐19 (Grein et Gerd Fätkenheuer, Re‐analysis of cumulative incidence of 15 May 2020 NEJM Letters to the editor International doi/full/10.1056/NEJMc NA Remdesivir al. ‐ NEMJ) Christian Hoffman, improvement, patient classification Jiayuan Wu 2015312

https://www.clinicalmicr To evaluate the performance of an Clinical obiologyandinfection.co A multiple center clinical evaluation of an ultra‐fast single Diagnostic clinical ultra‐fast single‐tube nucleic acid Preprint Microbiology China Ji Wang, et al. m/action/showPdf?pii=S NA Diagnostic test tube assay for SARS‐CoV‐2 RNA evaluation isothermal amplification detection and Infection 1198‐ assay for SARS‐CoV‐2 RNA 743X%2820%2930284‐6

Are combined oropharyngeal/nares Journal of A combined oropharyngeal/nares swab is a suitable https://www.sciencedir Oropharyngeal/nares Diagnostic assay swab is a suitable alternative for Preprint Clinical alternative to nasopharyngeal swabs for the detection of Canada Jason J., et al. ect.com/science/article/ NA and nasopharyngeal comparison nasopharyngeal swabs for COVID19 Virology SARS‐CoV‐2 swabs pii/S1386653220301840 sample colleciton?

Can an AI model rapidly identify SARS‐ https://www.nature.co CoV‐2 infection based on initial chest Artificial intelligence–enabled rapid diagnosis of patients 19 May 2020 Nature Diagnostic assay Chinq Xueyan Mei, et al. m/articles/s41591‐020‐ N/A AI diagnostic algorithm CT scans and associated clinical with COVID‐19 0931‐3 information of COVID‐19 (+) patients in the early stage?

To investigate the effects of dipeptidyl https://www.medrxiv.or dipeptidyl peptidase‐4 peptidase‐4 (DPP‐4i) and Effects of a DPP‐4 inhibitor and RAS blockade on clinical g/content/10.1101/2020 (DPP‐4i), 23‐May Medrxiv retrospective analysis South Korea Sang Youl Rhee et al. N/A renin–angiotensin system (RAS) outcomes of patients with diabetes and COVID‐19 .05.20.20108555v1.full.p renin–angiotensin blockade on the short‐term clinical system (RAS) blockade df outcomes of COVID‐19

https://www.medrxiv.or To investigate the prevalence of Do COVID‐19 patients admitted to the ICU require anti‐ prospective cohort g/content/10.1101/2020 anti‐Pneumocystis 22‐May Medrxiv France Alanio N/A Pneumocystis jirovecii in COVID‐19 Pneumocystis jirovecii prophylaxis? study .05.18.20105296v1.full.p jirovecii prophylaxis patients admitted to the ICU df

To develop and validate a novel RT‐ Development and clinical application of a rapid and https://www.medrxiv.or LAMP assay capable of detecting SARS‐ 23/05/2020 Medrxiv sensitive loop‐mediated isothermal amplification test for Diagnostic China Hu et al. g/content/10.1101/2020 N/A RT‐LAMP Diagnostic test CoV‐2 RNA for potential use in SARS‐CoV‐2 infection .05.20.20108530v2 centralized facilities and point‐of‐care settings

https://www.medrxiv.or Use of siltuximab in patients with COVID‐19 pneumonia g/content/10.1101/2020 Efficacy of siltuximab for treatment of 22 May 2020 Medrxiv retrospective analysis Italy, UK Gritti et al. NCT04322188 siltuximab requiring ventilatory support .04.01.20048561v3.full.p severe patients with COVID‐19 df

https://www.medrxiv.or To test if intravenous almitrine can Almitrine as a non ventilatory strategy to improve g/content/10.1101/2020 22‐May Medrxiv Case control series France Losser et al. N/A Almitrine improve hypoxia in mechanically intrapulmonary shunt in COVID‐19 patients .05.18.20105502v1.full.p ventilated COVID‐19 patients. df

https://www.medrxiv.or To examine the benefit‐risk profile of Remdesivir in treatment of COVID‐19: A systematic Systematic benefit‐risk g/content/10.1101/2020 remdesivir in COVID‐19 patients 12‐May MedRxiv UK Davies et al. N/A Remdesivir benefit‐risk assessment assessment .05.07.20093898v1.full.p compared to standard df of care, placebo or other treatments.

https://www.medrxiv.or To test the hypothesis that application Application of deep Assisting Scalable Diagnosis Automatically via CT Images g/content/10.1101/2020 of deep learning to 3D chest CT images 15‐May MedRxiv learning to China Liu et al. N/A Chest CT in the Combat against COVID‐19 .05.11.20093732v1.full.p could help identify COVID‐19 retrospective analysis df infections. https://www.medrxiv.or To explore the association of ACEi/ARB The effects of ARBs, ACEIs and statins on clinical g/content/10.1101/2020 and/or statins with clinical 15‐May MedRxiv outcomes of COVID‐19 infection among nursing home retrospective analysis Belgium De Spiegeleer et al. N/A ARBs, ACEi, Statins .05.11.20096347v1.full.p manifestations in COVID‐19 infected residents df older people residing in nursing homes.

https://www.medrxiv.or To analyse key safety metrics following Early Safety Indicators of COVID‐19 Convalescent Plasma expanded access g/content/10.1101/2020 transfusion of convalescent plasma in 14‐May MedRxiv USA Joyner et al. NCT04338360 Convalescent plasma in 5,000 Patients program .05.12.20099879v1.full.p patients with severe or life‐threatening df COVID‐19

https://www.medrxiv.or To report the clinical course, safety, Nebulized in‐line endotracheal dornase alfa and Nebulized in‐line and outcomes after nebulized in‐line retrospective case g/content/10.1101/2020 15‐May MedRxiv albuterol administered to mechanically ventilated COVID USA Weber et al. NCT04387786 endotracheal Dornase endotracheal dornase alfa treatment study .05.13.20087734v1.full.p 19 patients: A case series Alfa for intubated and mechanically df ventilated patients with COVID‐19.

https://www.medrxiv.or To determine if transfusion of Treatment of COVID‐19 Patients with Convalescent g/content/10.1101/2020 convalescent plasma is a safe 13‐May MedRxiv Case series USA Salazar et al. N/A Convalescent plasma Plasma in Houston, Texas .05.08.20095471v1.full.p treatment option for those with severe df COVID‐19 disease. http://viruseradication.c om/journal‐ Journal of Virus A review of the safety of favipiravir – a potential Victoria Pilkington, et details/A_review_of_the 30 April 2020 Systematic review UK NA Favipiravir Safety of favipiravir Eradication treatment in the COVID‐19 pandemic? al. _safety_of_favipiravir_% E2%80%93_a_potential_ treatment in the COVI To evaluate the safety and impact of Allogeneic cardiosphere-derived cells (CAP-1002) in https://link.springer.co administration of allogeneic CDCs, Basic Research 12 May 2020 critically ill Case series USA Siddharth Singh, et al. m/article/10.1007/s0039 NA CAP‐1002 formulated for intravenous (IV) in Cardiology COVID-19 patients: compassionate-use case series 5‐020‐0795‐1 infusion as CAP‐1002, in critically ill COVID‐19 patients.

Efficacy and safety of corticosteroids in COVID‐19 based Canadian https://www.cmaj.ca/co on evidence for COVID‐19, other coronavirus infections, Assess efficacy and safety of Medical Systematic Review ; International ntent/cmaj/early/2020/ Preprint influenza, community‐acquired pneumonia and acute Zhikang Ye, et al. NA Corticosteroids corticosteroids for COVID19, SARS, Association Meta‐analysis Collaboration 05/14/cmaj.200645.full. respiratory distress syndrome: a systematic review and MERS, CAP, ARDS and influenza Journal meta‐analysis pdf

Clinical and Pilot prospective open, single‐arm multicentre study on https://www.clinexprhe To assess the efficacy and safety of 1 May 2020 Experimental off‐label use of tocilizumab in patients with severe CT Italy S. Sciascia, et al. umatol.org/abstract.asp NA Tocilizumab tocilizumab in severe COVID19 patients Rheumatology COVID‐19 ?a=15723

Efficacy of different facial protection BMJ Global Facial protection for healthcare workers during Laura R Garcia https://gh.bmj.com/con 23 April 2020 Scoping Review USA NA Facial protection devices, especially in light of N95 Health pandemics: a scoping review Godoy, et al. tent/5/5/e002553 respirator shortages

Compassionate remdesivir treatment of severe Covid‐19 Pharmacologic pneumonia in intensive care unit (ICU) and Non‐ICU Spinello Antinori, et https://pubmed.ncbi.nl Comparative efficacy of remdesivir in Preprint Case series Italy NA Remdesivir al Research patients: Clinical outcome and differences in post al. m.nih.gov/32407959/ ICU and non‐ICU patients treatment hospitalisation status

To evaluate which type of full‐body PPE Personal protective equipment for preventing highly https://www.cochraneli and which method of donning or do.ing Cochrane infectious diseases due to exposure to contaminated International brary.com/cdsr/doi/10.1 PPE have the least risk of 15 April 2020 Systematic Review Verbeek JH, et al. NA PPE Library body fluids in healthcare Collaboration 002/14651858.CD01162 contamination or infection for HCW, staff 1.pub4/full and which training methods increase compliance with PPE protocols.

https://www.cochraneli To assess whether convalescent plasma Cochrane Convalescent plasma or hyperimmune immunoglobulin brary.com/cdsr/doi/10.1 or hyperimmune immunoglobulin 14 May 2020 Systematic Review Netherlands Valk SJ, et al. NA Convalescent Plasma Library for people with COVID‐19: a rapid review 002/14651858.CD01360 transfusion is eJective and safe in the 0/full treatment of people with COVID‐19.

Journal of https://www.jacionline. Preliminary assessment of the safety Allergy and Safety and efficacy of early high‐dose IV anakinra in Emanuele Pontali, et org/article/S0091‐ Preprint Case series Italy NA Anakinra and efficacy of anakirna in Clinical severe COVID‐19 lung disease al. 6749(20)30634‐ severe/moderate COVID19 Immunology 5/fulltext

Tocilizumab for Treatment of Severe COVID‐19 Patients: Microorganism https://pubmed.ncbi.nl What is the role of tocilizumab therapy 09 May 2020 Preliminary Results From SMAtteo COvid19 REgistry Observational study Italy Colaneri et al. NA tocilizumab s m.nih.gov/32397399/ in severe COVID‐19 patients? (SMACORE)

Hydroxychloroquine in Patients With Mainly Mild to https://www.bmj.com/c ChiCTR20000298 Is hydroxychloroquine effective and 14 May 2020 BMJ Moderate Coronavirus Disease 2019: Open Label, RCT China Tang et al. ontent/369/bmj.m1849.l Hydroxychloroquine 68 safe in COVID‐19 patients? Randomised Controlled Trial ong

Clinical efficacy of hydroxychloroquine in patients with https://www.bmj.com/c 05 May 2020 BMJ covid‐19 pneumonia who require oxygen: observational Observational study France Mahévas et al. NA Hydroxychloroquine Is hydroxychloroquine effective? ontent/369/bmj.m1844 comparative study using routine care data

https://www.medrxiv.or To assess and compare the Detection of SARS‐CoV‐2 antibodies using commercial performance of 6 rapid tests and 3 Clinical Evaluation of g/content/10.1101/2020 08 May 2020 MedRxiv assays and seroconversion patterns in hospitalized France Tuaillon et al. NCT04347850 Antibody diagnostic test ELISAs for the diagnosis of COVID‐19, diagnostic test .05.04.20090027v3.full.p patients and to explore seroconversions in df subjects with confirmed COVID‐19

https://www.medrxiv.or To compare the dynamic range and the ddPCR: a more sensitive and accurate tool for SARS‐CoV‐ Clinical evaluation of g/content/10.1101/2020 08 May 2020 MedRxiv China Suo et al. PCR diagnostic test limit of detection (LoD) between ddPCR 2 detection in low viral load specimens diagnostic test .02.29.20029439v2.full.p and RT‐PCR df

https://www.medrxiv.or To evaluate the efficacy and safety of Clinical Outcomes and Plasma Concentrations of g/content/10.1101/2020 ChiCTR20000295 baloxavir marboxil, adding baloxavir marboxil or favipiravir 05 May 2020 MedRxiv Baloxavir Marboxil and Favipiravir in COVID‐19 Patients: RCT China Yan Lou et al. .04.29.20085761v1.full.p 44 favipiravir to the current standard antiviral an Exploratory Randomized, Controlled Trial df treatment

https://www.medrxiv.or To determine if excessive PGE2 may be Celebrex adjuvant therapy on COVID‐19: An g/content/10.1101/2020 ChiCTR20000316 a key in the pathology of COVID‐19 and 11 May 2020 MedRxiv Clinical trial China Wenxin Hong et al. Celebrex (Celecoxib) experimental study .05.05.20077610v1.full.p 30 whether COX‐2 is a critical target for df therapy.

https://www.medrxiv.or To take into account the possible retrospective analysis confounders when analyzing the COVID‐19 Related Mortality: Is the BCG Vaccine Truly g/content/10.1101/2020 05 May 2020 MedRxiv of International Mexico Paredes et al. N/A BCG difference in mortality rates between Effective? .05.01.20087411v1.full.p mortality rates countries with and without history of a df universal BCG vaccination program. https://www.medrxiv.or zinc sulfate (as add‐on To determine if zinc sulfate added to Hydroxychloroquine and azithromycin plus zinc vs retrospective g/content/10.1101/2020 therapy to hydroxychloroquine and azithromycin 08 May 2020 MedRxiv hydroxychloroquine and azithromycin alone: outcomes USA Carlucci et al. N/A observational study .05.02.20080036v1.full.p hydroxychloroquine and may improve outcomes among in hospitalized COVID‐19 patients df azithromycin) hospitalized patients.

https://www.medrxiv.or To evaluate the effectiveness of the use Efficacy of face mask in preventing respiratory virus Systematic review and g/content/10.1101/2020 of masks to prevent laboratory‐ 05 May 2020 MedRxiv China Liang et al. N/A facemask transmission: a systematic review and meta‐analysis meta‐analysis .04.03.20051649v3.full.p confirmed respiratory virus df transmission.

Impact of corticosteroid therapy on outcomes of https://www.nature.co Evaluate the safety and efficacy of 5 May 2020 Nature persons with SARS‐CoV‐2, SARS‐CoV, or MERS‐CoV Meta‐analyisis China Huan Li, et al. m/articles/s41375‐020‐ NA Corticosteroids corticosteroids on SARS‐CoV‐2, SARS‐ infection: a systematic review and meta‐analysis 0848‐3.pdf CoV, and MERS‐CoV infections

Journal of https://www.biorxiv.org Can an efficient in‐silico trial base be Biomedical and In Silico Trial to test COVID‐19 candidate vaccines: a case Preprint Giulia Russo, et al. Italy Giulia Russo, et al. /content/10.1101/2020. NA Vaccine developed, and can it evaluate vaccine Health study with UISS platform candidates? Informatics 05.06.080630v1.full.pdf

Were non‐pharmaceutical Effect of non‐pharmaceutical interventions to contain https://www.nature.co Mathematical Non‐pharmaceutical interventions effective in reducing the Preprint Nature COVID‐19 in China China, UK, US Shengjie Lai, et al. m/articles/s41586‐020‐ NA Modeling interventions number of cases and speed of the 2293‐x_reference.pdf epidemic in mainland China?

Continuous hydroxychloroquine or colchicine therapy https://www.ncbi.nlm.ni Protective role of colchicine or Autoimmunity Omer Gendelman, et Colchicine, 29 April 2020 does not prevent infection with SARS‐CoV‐2: Insights Retrospective analysis Israel h.gov/pmc/articles/PMC NA hydroxychloriquine for COVID19 Reviews al. hydroxychloroquine from a large healthcare database analysis 7198406/ infection

Tocilizumab for the treatment of severe COVID‐19 https://www.sciencedir Is tocilizumab effective for improving Autoimmunity pneumonia with hyperinflammatory syndrome and ect.com/science/article/ Preprint Observational study Italy Paola Toniati, et al. NA Tocilizumab respiratory condition in severe Reviews acute respiratory failure: A single center study of 100 abs/pii/S1568997220301 COVID19? patients in Brescia, Italy 300

https://www.pnas.org/c Effective treatment of severe COVID‐19 patients with ontent/pnas/early/2020 Efficacy and safety of tocilizumab in April 29 2020 PNAS Retrospective analysis China Xiaoling Xua, et al. Tocilizumab tocilizumab /04/27/2005615117.full. sever COVID19 pdf

https://www.thelancet.c Triple combination of interferon beta‐1b, om/journals/lancet/artic interferon beta‐1b, lopinavir–ritonavir, and ribavirin in the treatment of 08 May 2020 The Lancet RCT Hong Kong Hung et al. le/PIIS0140‐ NCT04276688 lopinavir–ritonavir, The efficacy and safety of combination patients admitted to hospital with COVID‐19: an open‐ ribavirin label, randomised, phase 2 trial 6736(20)31042‐ 4/fulltext https://www.thelancet.c Interleukin‐1 blockade with high‐dose anakinra in om/journals/lanrhe/arti The Lancet patients with COVID‐19, acute respiratory distress 07 May 2020 Observational study Italy Cavalli et al. cle/PIIS2665‐ NCT04318366 anakinra Efficacy of anakinra Rheumatology syndrome, and hyperinflammation: a retrospective cohort study 9913(20)30127‐ 2/fulltext

https://www.sciencedir Journal of Supportive Treatment with Tocilizumab for COVID‐19: A ect.com/science/article/ Outcomes associated with TCZ 19 April 2020 Clinical Systematic Review USA Alzghari et al. NA NA Systematic Review pii/S1386653220301220 treatment in patients with COVID‐19 Virology ?via%3Dihub

https://www.clinicalmicr Umifenovir treatment is not associated with improved obiologyandinfection.co Effectiveness and safety of umifenovir 25 April 2020 Microbiology and outcomes in patients with coronavirus disease 2019: A Retrospective CT China N. Lian, et al. m/article/S1198‐ NA Umifenovir (Arbidol) for moderate COVID‐19 retrospective study 743X(20)30234‐ 2/fulltext

https://www.ncbi.nlm.ni Is Baricitinib an effective drug for Baricitinib therapy in COVID‐19: A pilot study on safety 16 April 2020 ournal of Infectio CT Italy Fabrizio Cantini, et al. h.gov/pmc/articles/PMC NA Baricitinib clinical and respiratory improvement in and clinical impact 7177073/ moderate COVID19 patients?

https://www.medrxiv.or Mandated Bacillus Calmette‐Guérin (BCG) vaccination g/content/10.1101/2020 Does BCG vaccination serve as a 04 May 2020 medRxiv growth curve analysis USA Berg et al. N/A BCG vaccination predicts flattened curves for the spread of COVID‐19 .04.05.20054163v5.full.p protective factor against COVID‐19 df

https://www.medrxiv.or regression analysis Does TB Vaccination Reduce COVID‐19 Infection? No g/content/10.1101/2020 To assess the effectiveness of BCG 22 April 2020 medRxiv based on USA/ Japan Fukui et al. N/A BCG vaccination Evidence from a Regression Discontinuity Analysis .04.13.20064287v1.full.p vaccination against COVID‐19 observational data df

https://www.medrxiv.or A Novel Protein Drug, Novaferon, as the Potential g/content/10.1101/2020 ChiCTR20000294 Novaferon, To determine the antiviral effects of 29 April 2020 medRxiv RCT China Fang Zheng et al. Antiviral Drug for COVID‐19 .04.24.20077735v1.full.p 96 Lopinavir/Ritonavir Novaferon for COVID‐19 df

To summarise the data on all currently https://www.medrxiv.or tested treatment and prevention Review and methodological analysis of trials currently all treatment and Greece, g/content/10.1101/2020 options for COVID‐19, and to 01 May 2020 medRxiv testing treatment and prevention options for the novel Systematic review Fragkou et al. N/A preparation options for France .04.27.20080226v1.full.p methodologically analyse and evaluate coronavirus disease (COVID‐19) globally. covid‐19 df the quality of the registered interventional studies

https://www.medrxiv.or Could hydroxychloroquine Hydroxychloroquine application is associated with a g/content/10.1101/2020 administration be beneficial in the 01 May 2020 medRxiv decreased mortality in critically ill patients with COVID‐ retrospective analysis China Bo Yu et al. N/A Hydroxychloroquine .04.27.20073379v1.full.p treatment of critically ill patients with 19 df COVID‐19?

https://www.medrxiv.or To determine if anti‐hypertensive drugs Hypertension and Renin‐Angiotensin‐Aldosterone g/content/10.1101/2020 anti‐hypertensive 29 April 2020 medRxiv retrospective analysis USA Ip et al. N/A are harmful or beneficial to Covid‐19 System Inhibitors in Patients with Covid‐19 .04.24.20077388v1.full.p agents patients with hypertension df

https://www.medrxiv.or To evaluate the antiviral efficacy of Lopinavir‐ritonavir alone or combined with arbidol in the g/content/10.1101/2020 lopinavir/ritonavir, lopinavir/ritonavir alone or combined 29 April 2020 medRxiv treatment of 73 hospitalized patients with COVID‐19: a retrospective analysis China Xiu Lan et al. N/A .04.25.20079079v1.full.p arbidol with arbidol in the treatment of pilot retrospective study df hospitalized patients with COVID‐19.

https://www.medrxiv.or Preliminary evidence from a multicenter prospective To assess the efficacy and safety of prospective g/content/10.1101/2020 04 May 2020 medRxiv observational study of the safety and efficacy of China Mingxing Huang et al. ChiCTR2000029609 Chloroquine chloroquine with different doses in observational study .04.26.20081059v1.full.p chloroquine for the treatment of COVID‐19 COVID‐19 df https://www.medrxiv.or To evaluate the effects of QT Interval Prolongation and Torsade De Pointes in g/content/10.1101/2020 Hydroxychloroquine, Hydroxychloroquine/Azithromycin on 01 May 2020 medRxiv Patients with COVID‐19 treated with retrospective analysis USA/Italy Chorin et al. N/A .04.27.20074583v1.full.p Azithromycin the QT interval and the arrhythmic risk Hydroxychloroquine/Azithromycin df in patients with SARS‐CoV‐2 infection.

https://www.medrxiv.or To assess and compare all nucleic acid‐ Performance & Quality Evaluation of Marketed COVID‐ diagnostic kit David Surace Kapitula g/content/10.1101/2020 01 May 2020 medRxiv China N/A qPCR Diagnostic test based COVID‐19 testing kits from 19 RNA Detection Kits evaluation et al. .04.25.20080002v1.full.p quality control perspectives df

To determine the relative risk of drug‐ azithromycin, https://www.medrxiv.or induced Long QT Syndrome (LQTS) Risk of drug‐induced Long QT Syndrome associated with chloroquine, favipiravir, g/content/10.1101/2020 associated with SARS‐CoV‐2 (COVID‐ 29 April 2020 medRxiv the use of repurposed COVID‐19 drugs: a systematic Systematic review USA/Canada Michaud et al. N/A hydroxychloroquine, .04.21.20066761v2.full.p 19) proposed repurposed drugs review lopinavir/ritonavir, compared to well‐known torsadogenic df remdesivir compounds retrospective analysis, https://www.medrxiv.or To evaluate the risk of overdose for Bayesian logostic Concentration‐dependent mortality of chloroquine in Thailand/ UK/ g/content/10.1101/2020 chloroquine treatment or prevention 29 April 2020 medRxiv regression, Watson et al. N/A Chloroquine overdose France .04.24.20078303v1.full.p regimens currently being trialled in pharmacodynamic COVID19 modelling df

https://www.thelancet.c Remdesivir in adults with severe COVID‐19: a om/journals/lancet/artic Effect of remdesivir in COVID‐19 29 April 2020 The Lancet randomised, double‐blind, placebo‐controlled, RCT China Wang et al. le/PIIS0140‐ NCT04257656 remdesivir patients multicentre trial 6736(20)31022‐ 9/fulltext

Academic A Rapid Systematic Review of Clinical Trials Utilizing https://onlinelibrary.wil Analyze current literature to find the 02 May 2020 Emergency Chloroquine and Hydroxychloroquine as a Treatment for Systematic review USA Chowdhury et al. ey.com/doi/abs/10.1111 NA NA role of CQ and HCQ Medicine COVID‐19. /acem.14005

https://www.medrxiv.or Clinical Efficacy of Intravenous Immunoglobulin Therapy intravenous To determine the clinical efficacy of retrospective cohort g/content/10.1101/2020 20 April 2020 medRxiv in Critical Patients with COVID‐19: A Multicenter China Ziyun Shao et al. N/A immunoglobulin (IVIG) intravenous immunoglobulin (IVIG) study .04.11.20061739v2.full.p Retrospective Cohort Study therapy therapy in COVID‐19 patients. df

Chloroquine dosing recommendations for https://ascpt.onlinelibra To establish best‐evidence to inform Clin Pharmacol pharmacokinetic 22 April 2020 pediatric COVID‐19 supported by modeling and Netherlands Verscheijden et al. ry.wiley.com/doi/10.100 N/A Chloroquine pediatric Chloroquine doses for Ther. (PBPK) model simulation. 2/cpt.1864 children infected with COVID‐19

Effect of High vs Low Doses of Chloroquine Diphosphate https://jamanetwork.co To evaluate the safety & efficacy of JAMA Network as Adjunctive Therapy for Patients Hospitalized With m/journals/jamanetwor 24 April 2020 RCT Brazil Borba et al NCT04323527 Chloroquine different dosages of chloroquine in Open Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐ kopen/fullarticle/276549 patients with severe COVID‐19. CoV‐2) Infection: A Randomized Clinical Trial. 9

A Randomized, Single‐blind, Group sequential, Active‐ https://www.medrxiv.or To evaluate the clinical efficacy and controlled Study to evaluate the clinical efficacy and g/content/10.1101/2020 ChiCTR20000298 21 April 2020 medRxiv RCT China Zhong et al. α‐Lipoic acid (ALA) safety of α‐Lipoic acid (ALA) for safety of α‐Lipoic acid for critically ill patients with .04.15.20066266v1.full.p 51 critically ill patients with COVID‐19. coronavirus disease 2019（COVID‐19） df

To systematically retrieve and https://www.medrxiv.or summarize the current evidence of the Effectiveness and Safety of Glucocorticoids to Treat Rapid review and 22 April 2020 medRxiv China Shuya Lu et al g/content/10.1101/2020 N/A Glucocorticoids effectiveness and safety of COVID‐19: A Rapid Review and Meta‐Analysis meta‐analysis .04.17.20064469v1 glucocorticoid therapy for patients with COVID‐19

https://www.medrxiv.or To assess the effectiveness of specific A systematic review of Anakinra, Tocilizumab, Sarilumab g/content/10.1101/2020 Anakinra, Tocilizumab, interleukin‐1 and ‐6 inhibitors for the 26 April 2020 MedRxiv Systematic review UK Khan et al N/A and Siltuximab for coronavirus‐related infections .04.23.20076612v1.full.p Sarilumab, Siltuximab treatment of coronavirus‐related df infections. https://www.cytodyn.co m/newsroom/press‐ Preliminary results Southern California Patients Treated with Leronlimab for releases/detail/415/sout 13 April 2020 Press release from clinical trial USA CytoDyn INC. NA leronlimab Could leronlimab be effective? COVID‐19 under Emergency IND hern‐california‐patients‐ treated‐with‐leronlimab‐ for

Transplantation of ACE2‐ Mesenchymal Stem Cells Aging and http://dx.doi.org/10.143 ChiCTR20000299 ACE2‐mesenchymal Efficacy of MSC transplantation in 28 February 2020 Improves the Outcome of Patients with COVID‐19 CT China Leng et al. Disease 36/AD.2020.0228 90 stem cell COVID patients Pneumonia

Journal of https://onlinelibrary.wil Tocilizumab treatment in COVID‐19: a single center What are treatment responses of TCZ 26 March 2020 Medical Observational study China Luo et al. ey.com/doi/full/10.1002 NA tocilizumab experience in the COVID‐19 patients? Virology /jmv.25801

Angiotensin‐converting Association of Inpatient Use of Angiotensin Converting To determine the association between https://www.ahajournal enzyme inhibitors Circulation Enzyme Inhibitors and Angiotensin II Receptor Blockers in‐hospital use of ACEI/ARB and all‐ 17 April 2020 Observational study China Zhang et al. s.org/doi/10.1161/CIRCR NA (ACEIs) and Angiotensin Research with Mortality Among Patients With Hypertension cause mortality in COVID‐19 patients receptor blockers Hospitalized With COVID‐19 ESAHA.120.317134 with hypertension (ARBs)

Angiotensin‐converting Association of Renin‐Angiotensin System Inhibitors With Asses the association between https://jamanetwork.co enzyme inhibitors Severity or Risk of Death in Patients With Hypertension ACEIs/ARBs and severity of illness and 23 April 2020 JAMA Case series China Juy Li, et al m/journals/jamacardiolo NA (ACEIs) and Angiotensin Hospitalized for Coronavirus Disease 2019 (COVID‐19) mortality in patients with hypertension receptor blockers Infection inWuhan, China gy/fullarticle/2765049 hospitalized for COVID‐19 infection. (ARBs)

Acta https://www.sciencedir Potential therapeutic effects of dipyridamole in the Is treatment with dipyridamol clinically PrePrint Pharmaceutica RCT China Xiaoyan Liu, et al. ect.com/science/article/ NA Dipyridamole severely ill patients with COVID‐19 effetive in severly ill COVID19 patients? Sinica B pii/S2211383520305529

https://www.medrxiv.or Benefits and Risks of Chloroquine and g/content/10.1101/2020 chloroquine/hydroxych To evaluate the efficacy and safety of 18 April 2020 medRxiv Hydroxychloroquine in The Treatment of Viral Diseases: meta‐analysis of RCTs China/ USA Jing Wang et al .04.13.20064295v1.full.p oroquine Chloroquine and hydroxychloroquine A Meta‐Analysis of Placebo Randomized Controlled Trials df

https://www.medrxiv.or To assess the effectiveness of hand Physical interventions to interrupt or reduce the spread Saudi Arabia, hygiene, surface disinfecting, and other systematic review and g/content/10.1101/2020 20 April 2020 medRxiv of respiratory viruses. Part 2 ‐ Hand hygiene and other Australia, Al‐Ansary NA hygiene interventions hygiene interventions in preventing or meta‐analysis .04.14.20065250v1.full.p hygiene measures: systematic review and meta‐analysis. Canada reducing the spread of illnesses from df respiratory viruses

https://www.medrxiv.or To investigate the efficacy and safety of An experimental trial of recombinant human interferon Recombinant human recombinant human interferon g/content/10.1101/2020 17 April 2020 medRxiv alpha nasal drops to prevent coronavirus disease 2019 in Clinical trial China Meng et al. NCT04320238 interferon‐alpha nasal alpha1b (rhIFN‐α) nasal drops in .04.11.20061473v1.full.p medical staff in an epidemic area drops healthy medical staff to prevent COVID‐ df 19. An exploratory randomized, controlled study on the https://www.medrxiv.or 23 March 2020, efficacy and safety of lopinavir/ritonavir or arbidol Lopinavir‐Ritonavir combination g/content/10.1101/2020 lopinavir/ritonavir updated 15 April medRxiv treating adult patients hospitalized with mild/moderate RCT China Li et al. NCT04252885 compared to Arbidol compared to no .03.19.20038984v2.full.p (Kaletra), arbidol 2020 COVID‐19 (ELACOI) antiviral treatment df

https://www.medrxiv.or Potential Effectiveness and Safety of Antiviral Agents in To assess the potential effectiveness review and meta‐ g/content/10.1101/2020 17 April 2020 medRxiv Children with Coronavirus Disease 2019: A Rapid Review China Shi et al. NA antivirals and safety of antiviral agents for COVID analysis .04.13.20064436v1.full.p and Meta‐Analysis 19 in children. df

https://www.medrxiv.or The aim of this review was to evaluate Efficacy and Safety of Antibiotic Agents in Children with g/content/10.1101/2020 17 April 2020 medRxiv rapid review China Wang et al NA antibiotics the efficacy and safety of antibiotic COVID‐19: A Rapid Review .04.13.20064402v1.full.p agents in children with COVID‐19 df

https://www.sciencedir Médécine et No evidence of rapid antiviral clearance or clinical ben‐ Is hydroxychloroquine effecitve for Prospective virological ect.com/science/article/ Hydroxychloroquine, Preprint Maladies efit with the combination of hydroxychloroquine and France JM Molina et al. NA viral clearance when reproducing the assay pii/S0399077X20300858 azithromycin Infectieuses azithromycin in patients with severe COVID‐19 infection study of Gautrel et al.? ?via%3Dihub

Grant from the https://www.sciencedir National Natural The effect of corticosteroid treatment on patients with Evaluate the influence of Accepted 31 Journal of ect.com/science/article/ Science coronavirus infection: a systematic review and meta‐ Meta‐analysis China Zhenwei Yang, et al. Corticosteroids corticosteroids in patients with March 2020 Infection pii/S0163445320301912 Foundation of analysis coronavirus. ?via%3Dihub China (Jing Liu, grant no.

Clinical https://academic.oup.co What is the best dose of Towards Optimization of Hydroxychloroquine Dosing in Preprint Infectious Prospective PK study France Sophie Perinel et al, m/cid/article/doi/10.109 NA Hydroxychloroquine hydroxychloroquine for COVID19 Intensive Care Unit COVID‐19 Patients Diseases 3/cid/ciaa394/5816960 patients?

https://academic.oup.co Journal of Is cholorquine better than Mingxing Huang, et m/jmcb/article/doi/10.1 Chloroquine, lopinavir, Molecular Cell Treating COVID‐19 with Chloroquine RCT China NA lopinavir/ritonavir in severe and al. 093/jmcb/mjaa014/581 ritonavir Biology moderate COVID19 patients? 4655

https://www.nejm.org/ Compassionate Use of Remdesivir for Patients with UK, Canada, 10 April 2020 NEJM Report Grein et al. doi/full/10.1056/NEJMo NA Remdesivir NA Severe Covid‐19 Europe, Japan a2007016

https://www.sciencedir Summary of the existing the evidence Journal of A systematic review on the efficacy and safety of Andrea Cortegiani, et ect.com/science/article/ 10 March 2020 Systematic review Italy NA Chloroquine on chloroquine for the treatment of Critical Care chloroquine for the treatment of COVID‐19 al. pii/S0883944120303907 COVID‐19 ?via%3Dihub

Systematic review of the clinical Journal Systematic review of the efficacy and safety of https://onlinelibrary.wil outcomes of using antiretroviral drugs Preprint International antiretroviral drugs against SARS, MERS, or COVID‐19: Systematic review Switzerland N Ford et al. ey.com/doi/10.1002/jia2 NA Antiretroviral drugs for the prevention and treatment of AIDS Society initial assessment .25489 coronaviruses and planned clinical trials Ethics Investigate the effects of 6‐week committees of Complementar https://www.sciencedir respiratory rehabilitation training on Respiratory rehabilitation in elderly patients with COVID‐ Non‐interventional Hainan General Respiratory 30 March 2020 y Therapies in China Kai Liu, et al. ect.com/science/article/ respiratory function, QoL, mobility and 19: A randomized controlled study RCT Hospital and rehabilitation training Clinical Practice pii/S1744388120304278 psychological function in elderly Huanggang patients with COVID‐19 Central Hospital

Complementar https://www.sciencedir Progressive muscle Investigate the effect of progressive Effects of progressive muscle relaxation on anxiety and Non‐interventional 6 March 2020 y Therapies in China Kai Liu, et al. ect.com/science/article/ NA relaxation (sleep muscle relaxation on anxiety and sleep sleep quality in patients with COVID‐19 RCT Clinical Practice pii/S1744388120302784 therapy) quality of COVID‐19 patients

https://www.medrxiv.or First Clinical Study Using HCV Protease Inhibitor g/content/10.1101/2020 Effect of danoprevir in moderate 24 March 2020 MedRxiv Danoprevir to Treat Naïve and Experienced CT China Chen et al. NCT04291729 danopevir/ritonavir .03.22.20034041v1.full.p COVID‐19 patients COVID‐19 Patients df

The potential of low molecular weight heparin to https://www.medrxiv.or 07 April 2020 MedRxiv mitigate cytokine storm in severe covid‐19 patients: a Retrospective CT China Chen Shi et al. g/content/10.1101/2020 not found enoxaparin Efficacy of enoxaparin retrospective clinical study .03.28.20046144v2

No evidence of clinical efficacy of hydroxychloroquine in https://www.medrxiv.or To assess the effectiveness of patients hospitalised for COVID‐19 infection and Matthieu Mahévas et g/content/10.1101/2020 14 April 2020 MedRxiv Retrospective analysis France NA Hydroxychloroquine Hydroxychloroquine in patients with requiring oxygen: results of a study using routinely al. .04.10.20060699v1.full.p severe Covid‐19 collected data to emulate a target trial df

Grants: National Science and https://jamanetwork.co Is plasma from convalescente patients Treatment of 5 critically ill patients with COVID‐19 with Technology 27 March 2020 JAMA Observational study China C Shen, et al. m/journals/jama/fullarti Convalescent plasma beneficial for critically ill COVID19 convalescent plasma Major Project cle/2763983 patients? (2018ZX1071100 1, Proceedings of the National https://www.pnas.org/c Is treatment with convalescent plasma Academy of The feasibility of convalescent plasma therapy in severe Observational/retrosp ChiCTR20000300 6 April 2020 China Kai Duan et al ontent/early/2020/04/0 Convalescent plasma safe and beneficial for COVID19 Sciences of the COVID‐19 patients: a pilot study ective control 48 2/2004168117 patients? United States of America Compare medical masks to N95 Influenza and Medical Masks vs N95 Respirators for Preventing COVID‐ https://onlinelibrary.wil respirators in preventing laboratory other Jessica J Bartoszko, et N95 respirators vs Preprint 19 in Health Care Workers ‐ A Systematic Review and Systematic review Canada ey.com/doi/pdf/10.1111 NA confirmed viral infection and Respiratory al. surgical masks Meta‐Analysis of Randomized Trials respiratory illness including coronavirus Viruses /irv.12745 specifically in health care workers. https://www.cambridge. Is attending one live training session or Disaster RANDOMIZED TRIAL OF INSTRUCTOR‐LED TRAINING org/core/journals/disast watching video trainings over a month Medicine and VERSUS VIDEO LESSON IN TRAINING HEALTH CARE er‐medicine‐and‐public‐ Training on personal Preprint RCT Denmark L Christensen et al NA more effective for training on downing Public Health PROVIDERS IN PROPER DONNING AND DOFFING OF health‐ protective equipment and doffing personal protective Preparedness PERSONAL PROTECTIVE EQUIPMENT preparedness/article/ra equipment? ndomized‐trial‐of‐

Journal of Performance of VivaDiagTM COVID‐19 IgM/IgG Rapid https://onlinelibrary.wil To assess an easy to perform Diagnostic serological Preprint Medical Test is inadequate for diagnosis of COVID‐19 in acute Diagnostic assay Italy Irene Cassantini et al. ey.com/doi/epdf/10.100 NA serological assay for diagnosis of assay Virology patients referring to emergency room department 2/jmv.25800 COVID19

DOI: 10.1128/JC M.00461‐20; Joural of https://jcm.asm.org/con Evaluation of Nucleocapsid and Spike Protein‐based Hospital Ethics Diagnostic serological Evaluate the diagnostic feasibility of Preprint Clinical Diagnostic assay China Wanbing Liu, et al. tent/early/2020/03/27/J ELISAs for detecting antibodies against SARS‐CoV‐2 Committee of the assay two ELISA assays Microbiology CM.00461‐20 General Hospital of the Central Article originally Australian New published in Zealand Clinical To compare the efficacy of cloth masks A cluster randomised trial of cloth masks compared with Australia https://bmjopen.bmj.co medical masks, cloth 2015; authors BMJ Open RCT MacIntyre CR et al. Trials Registry: to medical masks in hospital healthcare medical masks in healthcare workers /Vietnam m/content/5/4/e006577 masks added comment ACTRN12610000 workers on 30/03/2020 887077.

https://www.medrxiv.or Efficacy of hydroxychloroquine in patients with COVID‐ ChiCTR20000295 Assess the efficacy of 31 March 2020 MedRxiv RCT China Zhaowei Chen et al. g/content/10.1101/2020 Hydroxychloroquine 19: results of a randomized clinical trial 59 hydroxychloroquine .03.22.20040758v2

Clinical and microbiological effect of a combination of https://www.mediterra Assess the efficacy of hydroxychloroquine and azithromycin in 80 COVID‐19 nee‐infection.com/wp‐ Hydroxychloroquine, Preprint RCT France Gautret et al. NA hydroxychloroquine associated with patients with at least a six‐day follow up: an content/uploads/2020/0 Azithromycin azithromycin observational study 3/COVID‐IHU‐2‐1.pdf

An exploratory randomized, controlled study on the 23 March 2020 efficacy and safety of lopinavir/ritonavir or arbidol https://www.medrxiv.or Lopinavir‐Ritonavir combination lopinavir/ritonavir (preprint, not yet BMJ treating adult patients hospitalized with mild/moderate RCT China Li et al. g/content/10.1101/2020 NCT04252885 compared to Arbidol compared to no (Kaletra), arbidol peer‐reviewed) COVID‐19 (ELACOI) .03.19.20038984v1 antiviral treatment

ChiCTR20000299 39, Breakthrough: Chloroquine phosphate has shown https://www.jstage.jst.g ChiCTR20000299 10 Feb 2020 Biosci Trends apparent efficacy in treatment of COVID‐19 associated Summary of 15 CTs China Gao et al. o.jp/article/bst/14/1/14 Chloroquine Could chloroquine be effective? 35, pneumonia in clinical studies. _2020.01047/_article ChiCTR20000298 99, https://www.cytodyn.co m/newsroom/press‐ Three Additional Patients with Severe COVID‐19 Treated Preliminary results not published releases/detail/401/thre 30 March 2020 with Leronlimab in New York Medical Center Bringing the from clinical trial USA CytoDyn Inc. NA Leronlimab Could leronlimab be effective? yet e‐additional‐patients‐ Total to 10 Patients with‐severe‐covid‐19‐ treated‐with

https://www.medrxiv.or Favipiravir versus Arbidol for COVID‐19: A Randomized ChiCTR20000302 Conventional therapy + favipiravir or 27 March 2020 medRxiv RCT China Chang Chen et al. g/content/10.1101/2020 Favipiravir, Arbidol Clinical Trial 54 arbidol? .03.17.20037432v2

International https://www.sciencedir Hydroxychloroquine and azithromycin as a treatment of Journal of ect.com/science/article/ EudraCT number Hydroxychloroquine, Role of hydroxychloroquine on 20 March 2020 COVID‐19: results of an open‐label non‐randomized CT France Gautret et al. Antimicrobial pii/S0924857920300996 2020‐000890‐25 Azithromycin respiratory viral loads clinical trial Agents #!

https://www.ncbi.nlm.ni A Trial of Lopinavir‐Ritonavir in Adults Hospitalized with ChiCTR20000293 lopinavir/ritonavir Lopinavir‐Ritonavir combination 19 March 2020 N Engl J Med RCT China Cao et al. h.gov/pubmed/3218746 Severe Covid‐19. 08 (Kaletra) compared to conventional therapy ? 4

https://www.sciencedir Journal of Arbidol combined with LPV/r versus LPV/r alone against Retrospective cohort ect.com/science/article/ Lopinavir/ritonavir, Arbidol and lopinavir‐ritonavir 11 March 2020 China Lisi Deng NA Infection Corona Virus Disease 2019: A retrospective cohort study study pii/S0163445320301134 Arbidol compared to lopinavir‐ritonavir only? ?via%3Dihub

https://bjanaesthesia.or What is the efficacy and safety of high‐ High‐flow nasal‐oxygenation‐ assisted fibreoptic tracheal British Journal g/article/S0007‐ ChiCTR20000296 High‐flow nasal flow nasal oxygenation during In press intubation in critically ill patients with COVID‐19 RCT China Cai‐Neng Wu et al. of Anaesthesia 0912(20)30135‐ 58 oxygnation fibreoptic bronchoscopic intubation in pneumonia: a prospective randomised controlled trial 5/fulltext critically ill patients with COVID‐19?

Chinese Journal 2020 Pre‐print Efficacy of lopinavir, ritonavir and Arbidol for the http://rs.yiigle.com/yufa Lopinavir/ritonavir, Efficacy of lopinavir/ritonavir and of Infectious Retrospective analysis China Chen Jun et al. NA online treatment of new coronavirus pneumonia biao/1182592.htm Arbidol arbidol Diseases,

Journal of Zhejiang http://www.zjujournals. A pilot study of hydroxychloroquine in treatment of University com/med/CN/10.3785/j. Role of hydroxychloroquine on 2020 patients with common coronavirus disease‐19 (COVID‐ RCT China Chen Jun et al. NCT04261517 Hydroxychloroquine (Medical issn.1008‐ respiratory viral loads 19) Science) 2020 9292.2020.03.03 , Vol. 49 Issue

Assess the efficacy and safety of Meplazumab treats COVID‐19 pneumonia: an open‐ https://doi.org/10.1101/ meplazumab, a humanized anti‐CD147 2020 Pre‐print MedRxiv CT China Huijie Bian et al. NCT 04275245 Meplazumab labelled, concurrent controlled add‐on clinical trial 2020.03.21.20040691 antibody, as add‐on therapy in patients with COVID‐19 pneumonia.

Total